

Fig. 1. Spontaneous mutant frequencies of the *red/gam* and *gpt* genes in the liver of *Parp-1*<sup>-/-</sup> and *Parp-1*<sup>+/+</sup> mice at 4 and 18 months of age. (A) Spontaneous mutant frequencies of the *red/gam* genes in the livers. (B) Spontaneous mutant frequencies in the *gpt* genes of the livers. Error bars represent standard error values. (C) Effect of *Parp-1* deficiency on the mutation spectrum of the *red/gam* genes in the liver at 18 months of age. Specific mutation frequencies in the *red/gam* genes of the livers are shown. Mean values and standard error values are presented for *Parp-1*<sup>-/-</sup> and *Parp-1*<sup>+/+</sup> mice ( $n = 6$  and  $4$ , respectively). (D) Distribution of single base deletion mutations in the *gam* gene of the livers at 18 months of age. Single base deletions were observed on non-repeat, or 2–3 base repeats, or 4–6 base repeats as indicated in the figure as repeat length ( $N_n$ ) of 1, 2, 4–6, respectively.

*Parp-1*<sup>-/-</sup> mice, but not in *Parp-1*<sup>+/+</sup> mice in the liver at 18 months old. As shown in Table 1, the frequencies of complex-type deletions in *Parp-1*<sup>-/-</sup> mice showed a higher tendency than those in *Parp-1*<sup>+/+</sup> mice, although it is not statistically significant ( $p = 0.224$ ). The structures of complex-type mutations of *Parp-1*<sup>-/-</sup> mice observed at 18 months of age are shown in Table 2. Two complex-type deletions

observed in *Parp-1*<sup>-/-</sup> mice accompanied both small insertions and microhomologous sequences at deletion junctions (Table 2). It is of note that complementary nucleotides AAA (G61-1-3) or TT (G93-2-3) (marked with upper lines in Table 2) are present at the 5' position to these microhomologous deletion junctions in each case.

**Table 1**  
Spectrum of the mutations of two bases or more in the *red/gam* genes in the liver and brain of *Parp-1*<sup>-/-</sup> mice at 18 months old.

Tissue	Deletion	<i>Parp-1</i> <sup>+/+</sup>		<i>Parp-1</i> <sup>-/-</sup>	
		Mutation frequency ( $\times 10^{-6}$ )	No. of mutants (MEJ/Non-MEJ)	Mutation frequency ( $\times 10^{-6}$ )	No. of mutants (MEJ/Non-MEJ)
Liver	Simple	0.34 $\pm$ 0.21	3 (2/1)	0.96 $\pm$ 0.27	13 (6/7)
	Complex	<0.16	0	0.13 $\pm$ 0.08	2 (2/0)
	with small insertion <sup>a</sup>	<0.16	0	0.13 $\pm$ 0.08	2 (2/0)
	with recombination	<0.16	0	<0.13	0
Brain	Simple	0.15 $\pm$ 0.15	1 (0/1)	0.32 $\pm$ 0.14	3 (2/1)
	Complex	<0.18	0	0.32 $\pm$ 0.14	3 (1/1) <sup>*</sup>
	with small insertion	<0.18	0	0.19 $\pm$ 0.12	2 (1/1)
	with recombination	<0.18	0	0.12 $\pm$ 0.12	1

MEJ; microhomology-mediated end joining. Non-MEJ; non-microhomology-mediated end joining.

<sup>a</sup> Small insertion represents 4–9 bp insertion.

<sup>\*</sup> One of the mutants could not be classified into MEJ or non-MEJ type.

### 3.3. Mutation frequencies of the *red/gam* gene in the brains at 4 and 18 months of age

*Parp-1*<sup>-/-</sup> mice showed 1.5-fold higher mutant frequencies compared to *Parp-1*<sup>+/+</sup> mice ( $p=0.047$ ) in the brains at 4 months of age (Fig. 2A). The brains of *Parp-1*<sup>-/-</sup> mice showed a 2.2-fold higher tendency of mutant frequencies than those in *Parp-1*<sup>+/+</sup> mice ( $p=0.088$ ) at 18 months of age (Fig. 2A). The tendency of age-dependent slight increase in the mutant frequency in the brain was observed in *Parp-1*<sup>-/-</sup> but not in *Parp-1*<sup>+/+</sup> mice, as mentioned earlier in the case with the liver. Analysis of the mutation spectrum in the brain (Fig. 2C) revealed some differences from that of the livers. In the brain, a tendency of increase in base substitution and deletion mutations of two bases or more was observed in *Parp-1*<sup>-/-</sup> mice compared to *Parp-1*<sup>+/+</sup> mice (base substitution:  $p=0.055$ , deletion mutation:  $p=0.11$ ). Different from the cases in the liver, the frequency of single base deletions at non-repeat or 2–3 bp repeats is not increased in the brain of *Parp-1*<sup>-/-</sup> mice at 18 months of age compared to *Parp-1*<sup>+/+</sup> mice (Fig. 2C).

### 3.4. Lower mutation frequencies of the *gpt* gene in the brains of *Parp-1*<sup>-/-</sup> than *Parp-1*<sup>+/+</sup> mice at 4 months of age and age-dependent increase

Of note, mutant frequencies of the *gpt* gene in the brains of *Parp-1*<sup>-/-</sup> mice were lower than those of *Parp-1*<sup>+/+</sup> mice ( $p=0.009$ ) at 4

months of age (Fig. 2B). No pathological changes in the brains were observed in *Parp-1*<sup>-/-</sup> and *Parp-1*<sup>+/+</sup> mice. Mutation spectra in the brains of *Parp-1*<sup>-/-</sup> mice showed a lower frequency of G:C to A:T base transition mutations ( $p=0.047$ ) as well as deletion mutations ( $p=0.034$ ) compared to *Parp-1*<sup>+/+</sup> mice at 4 months old (Fig. 2D).

The *gpt* mutant frequency showed an increase at 18 months of age in the *Parp-1*<sup>-/-</sup> but not in *Parp-1*<sup>+/+</sup> mice ( $p=0.011$ , Fig. 2B). There was no difference in the mutant frequencies of the *gpt* gene in the brain between *Parp-1*<sup>-/-</sup> and *Parp-1*<sup>+/+</sup> mice at 18 months of age (Fig. 2B).

Comparison of the mutation spectra between 4 and 18 months of age in *Parp-1*<sup>-/-</sup> mice suggests a tendency of age-dependent increase in the frequencies of deletion mutations ( $p=0.068$ , Fig. 2D). A tendency of increase of point mutation ( $p=0.144$ ) is also noticed, suggesting that *Parp-1* may be involved in suppressing age-dependent introduction of point mutations in the brain.

## 4. Discussion

Spontaneous *gpt* and *red/gam* mutant frequencies are reported to be around  $2-6 \times 10^{-6}$  and  $1-5 \times 10^{-6}$ , respectively, in *gpt* delta mice of C57BL/6 genetic background [23,24]. In this study, the spontaneous mutation frequencies of *gpt* and *red/gam* mutant frequencies in the liver and the brain of *Parp-1*<sup>+/+</sup> are both around  $2 \times 10^{-6}$  at 4 months of age and thus consistent with the previous reports. The mutant frequency of the *gpt* gene in the small intestine

**Table 2**  
Junctional sequences of complex-type mutations in the liver and brain of *Parp-1*<sup>-/-</sup> mice at 18 months old.

Tissue	Mutant ID <sup>a</sup>	Original sequence in lambdaEG10	Junctional sequence of mutation	Deletion/insertion size (nucleotide position in lambdaEG10)
Liver	G61-1-3	5'-GTCATCAAA <b>cc</b> cc-3' 3'-CAGTAGTTT <b>gg</b> gtg	5'-GTCATCAAA <b>cc</b> cc-3' 3'-CAGTAGTTT <b>gg</b> gtg	20 bp deletion + 4 bp insertion (25021–25040)
	G93-2-3	5'-CCGTGGCGTT <b>ch</b> ha-3' 3'-GGCACCGCAA <b>cg</b> tt	5'-CCGTGGCGTT <b>ch</b> ha-3' 3'-GGCACCGCAA <b>cg</b> tt	149 bp deletion + 6 bp insertion (25058–25206)
Brain	G61-1-1	5'-TTCATTAGACT <b>tt</b> at-3' 3'-AAGTAATCT <b>g</b> aata	5'-TTCATTAGACT <b>tt</b> at-3' 3'-AAGTAATCT <b>g</b> aata	3694 bp deletion + 6 bp insertion (21600–25293)
	G94-1-1	5'-TGTCTGCAT <b>g</b> aa-3' 3'-ACAGACGTA <b>ct</b> ct	5'-TGTCTGCAT <b>g</b> aa-3' 3'-ACAGACGTA <b>ct</b> ct	3805 bp deletion + 9 bp insertion (21682–25486)
	G93-2-4	5'-agc <b>g</b> CCCA <b>g</b> CTCT-3' 3'-tgc <b>g</b> CGGT <b>g</b> CGAGA-5'	5'-taagag <b>g</b> tcag <b>g</b> CCCA <b>g</b> CTCT-3' 3'-att <b>ct</b> cg <b>g</b> tc <b>g</b> CGGT <b>g</b> CGAGA-5'	Recombination with unknown sequence

<sup>a</sup>ID; Identification number. Red and blue letters indicate deleted and inserted sequences, respectively. Letters in the box are microhomologous sequences. Upperlines show complementary mononucleotide sequences at 5' positions of the microhomologous sequences.




Fig. 2. Spontaneous mutant frequencies of the *red/gam* and *gpt* genes in the brain of *Parp-1*<sup>-/-</sup> and *Parp-1*<sup>+/+</sup> mice at 4 and 18 months of age. (A) Spontaneous mutant frequencies of the *red/gam* genes. (B) Spontaneous mutant frequencies in the *gpt* genes. Error bars represent standard error values. (C) Mutation spectra of the *red/gam* genes in the brain of *Parp-1*<sup>-/-</sup> and *Parp-1*<sup>+/+</sup> mice at 18 months of age. (D) Mutation spectra of the *gpt* genes in the brain of *Parp-1*<sup>-/-</sup> and *Parp-1*<sup>+/+</sup> mice at 4 and 18 months of age.

of *gpt* delta transgenic mice of mixed genetic background of SWR and C57BL/6 is reported to be  $2.5 \times 10^{-5}$  [22], which is higher compared to other reports on *gpt* delta mice [23,24]. This difference could be due to the mouse strain, tissues or other factors. From 4 to 18 months of age, the mutant frequency of the *gpt* gene in *Parp-1*<sup>+/+</sup> mice increased 2-fold. The mutant frequency of the *lacZ*

marker gene in the liver is around  $5 \times 10^{-6}$  at 4–6 months of age and  $1.2 \times 10^{-5}$  at 24–34 months of age in wild-type mice [19]. Therefore age-dependent 2-fold increase in mutant frequency is consistently observed both in the *gpt* and *lacZ* [19] genes. On the other hand, size change mutations in the liver detected by the *lacZ* gene system did not significantly increase before 25–27 months [19] but

increased thereafter. Increase of mutant frequency in the *red/gam* gene in *Parp-1<sup>+/-</sup>* mice at 18 months of age, which detects deletion mutation, was not observed in the liver, being consistent with the results in the *lacZ* gene system [19]. In the *lacZ* gene system, the target size is around 3000 bp, whereas that in the *gpt* and *red/gam* gene (*Spi<sup>-</sup>* assay) are around 456 and 417 bp, respectively. The smaller size of the target sequences of the *gpt* and *red/gam* genes could be also responsible for the lower spontaneous mutant frequencies.

In this study, *Parp-1<sup>-/-</sup>* mice showed a tendency of higher frequencies of spontaneous deletion mutations in the *red/gam* gene, including complex-type deletions in the liver ( $p=0.20$ ) and brain ( $p=0.29$ ) at 18 months of age.

The single base deletion mutations at non-repeat or short repeat sequences of the *red/gam* gene showed a 5.8-fold increase ( $p=0.031$ ) in the liver of *Parp-1<sup>-/-</sup>* mice compared to *Parp-1<sup>+/-</sup>* mice at 18 months of age. The frequency of deletion mutations of two bases or more also showed a 3.2-fold higher tendency in the *Parp-1<sup>-/-</sup>* than in the *Parp-1<sup>+/-</sup>* liver ( $p=0.084$ ). We observed complex-type deletions in the livers and brains of *Parp-1<sup>-/-</sup>* but not in *Parp-1<sup>+/-</sup>* mice at 18 months old.

8-Oxodeoxyguanosine (8-oxodG) is one outcome of major oxidative DNA damage [31]. The 8-oxodG levels in DNA of the liver, lungs, and small intestine in double knockout mice lacking both 8-oxoguanine DNA glycosylase 1 (*Ogg1*) and Mut Y homologue (*Myh*) genes increased linearly between 4 and 14 months of age [32]. 8-OxodG and SSB, which are expected outcomes of major endogenous DNA damage, are preferentially repaired by BER. *Parp-1* is shown to be involved in BER and deletion mutations of single base and larger sizes of deletion as well as complexed-type were increased in *Parp-1<sup>-/-</sup>* mice after treatment with an alkylating agent, BHP [20]. The frequency of single base deletion mutations at non-repeat or short repeat sequences of the *red/gam* gene also increased 2.9-fold in *Parp-1<sup>-/-</sup>* mice compared to *Parp-1<sup>+/-</sup>* mice ( $p=0.043$ ) in the liver after treatment of the alkylating agent, whereas no difference in the frequency of single base deletion at 4–6 bp of mononucleotide repeats was observed between genotypes [20]. Therefore the spectra of single base deletions in the liver of *Parp-1<sup>-/-</sup>* mice at advanced age and after treatment with the alkylating agent are similar to each other. Stalled BER in the absence of *Parp-1* at a SSB introduced

step may further cause deletion mutations after treatment with an alkylating agent [20]. Therefore, there is a possibility that deletion mutation is also caused through BER induced by endogenous DNA damage during aging in *Parp-1<sup>-/-</sup>* mice. After introduction of SSB during BER, lack of *Parp-1* may induce stall or delay in BER and terminal nucleotides may be destabilized and lost under *Parp-1* deficiency by exonuclease activity (Fig. 3). Collision between SSB and replication forks induces double strand breaks (DSBs) [33]. Two SSBs on opposite strands within at least 30 nt could resolve into a DSB [34]. Therefore, an increase of spontaneous DSBs might also be caused by the presence of SSBs during replication fork progression or defective BER under *Parp-1* deficiency.

Deletion mutations including single base deletions may be also produced during imprecise non-homologous end joining (NHEJ). In NHEJ reconstituted systems that utilize DSB substrates, it is shown that deletion or insertion of single bases as well as larger sizes occurs during the NHEJ process [35–37]. In chicken DT-40 cells, *Parp-1* negatively regulates the NHEJ process by inhibiting Ku70/Ku80 action, and *Parp-1* deficiency causes an increase of NHEJ frequency [38]. However, DT-40 cells are known to have high HR levels compared to typical mammalian somatic cells. Using mouse embryonic fibroblast or CHO cells, it is demonstrated that *Parp-1* competes with Ku for DSB binding and is shown to be involved in a backup pathway of classical NHEJ pathway with DNA ligase III [39]. Therefore, as shown in Fig. 3, during a NHEJ process of DSB, terminal nucleotides may be destabilized in the absence of *Parp-1*, and resection of bases by the exonuclease may lead to deletion mutation.

It is also notable that the frequency of single base deletions at 4–6 bp mononucleotide repeats did not show a difference between either genotypes in the livers and brains. Single base deletion mutations at 4–6 bp of mononucleotide repeats, namely at run sequences, might be caused by slippage error during DNA replication or repair reaction. The results suggest that *Parp-1* is not essential to suppress these slippage type errors induced during aging.

Two complex-type deletions observed in *Parp-1<sup>-/-</sup>* mice accompanied small insertions as well as microhomologous sequences at deletion junctions, suggesting that these mutations could be




Fig. 3. A model for augmented development of deletion mutation through imprecise BER or NHEJ process in the absence of *Parp-1*. During BER, after single strand breaks are introduced following damaged base removal, the DNA terminus may be destabilized in the absence of *Parp-1*. Base loss could occur by the DNA exonuclease activity. When misannealing and ligation occur, the deletion will be fixed by subsequent DNA replication. Stalled BER reaction in the absence of *Parp-1* on single strand breaks may also cause DSB and may induce switching to a NHEJ reaction and subsequently base loss will be fixed by end-joining process. During DSB repair process by NHEJ, base loss frequency might be augmented at the destabilized DNA terminus in the absence of *Parp-1*.

caused by insertion of a few nucleotides during microhomologous end-joining (MEJ)-type reactions. A few complementary bases are present at the 5' position of the microhomologous sequences (marked with upper lines in Table 2). During the end-joining process, after resection of strand ends, transient base-pairing at microhomologous sequences may occur and a few complementary bases at the 5' position may also form base-pairing. In the absence of Parp-1, these base-pairings may be destabilized and resection and insertion of a few bases may tend to occur in the livers. Consistently of all seven simple-type deletions of two bases or more observed in the livers of *Parp-1*<sup>-/-</sup> mice (Table 1), none harbored a few complementary bases at the 5' position of the microhomologous sequences (data not shown). On the other hand, in two simple-type deletions of two bases or more in *Parp-1*<sup>+/+</sup> mice, one deletion harbored a few complementary bases at the 5' position of the microhomologous deletion junctions (Table 1).

In the brain, one out of three complex-type deletions of *Parp-1*<sup>-/-</sup> mice harbored microhomologous deletion junctions but did not harbor complementary bases at 5' positions of the microhomologous deletion junctions. This point should be further evaluated by analyzing deletion mutations induced after treatment with various types of DNA damaging agents in different tissues.

The xeroderma pigmentosum complementation group A (*Xpa*) plays an important role in nucleotide excision repair (NER) and *Xpa*-deficient mice also show higher spontaneous mutant frequencies in the liver at advanced ages [40]. In fact, *Xpa*-deficient mice show an increased frequency of hepatocellular adenomas at older ages [34]. It is thus possible that endogenous DNA damage repairable by NER may occur during aging. However, no increase in the susceptibility to carcinogenesis induced in *Parp-1*<sup>-/-</sup> mice by 4-nitroquinoline 1-oxide [41], which induces bulky DNA adducts, suggests that Parp-1 is not involved in NER.

Most liver cells stay in the G0 phase and they usually enter the cell division cycle after various stimulating events. An augmented frequency of DNA replication, like that in preneoplastic lesions, can also increase the chance of DSBs and may increase the frequency of deletions. Two of six *Parp-1*<sup>-/-</sup> mice used in the mutation analysis harbored tumors in the liver and the tumor regions were not included for DNA isolation. Because the frequencies and spectrum of mutations in the *gpt* or *red/gam* genes were unbiased in each mouse, we can exclude the possibility that the tissues used for isolation of DNA contained monoclonally proliferating preneoplastic lesions or other cycling cells.

It is also possible that an increased frequency of cell division may be causative of augmented frequency of DSBs and may result in a higher frequency of deletion mutation. However, if this is true, the observed mutation spectrum is expected to be the same between the genotypes. We could rule out this possibility because we observed different spectra of deletion mutations between the genotypes.

Unexpectedly we also found a 3-fold lower frequency of point mutations in adolescent *Parp-1*<sup>-/-</sup> compared to *Parp-1*<sup>+/+</sup> mice in the brain ( $p=0.009$ ). An age-dependent increase in the mutant frequency in *Parp-1*<sup>-/-</sup> mice was also shown ( $p=0.011$ ). Lower frequencies of G:C to A:T type mutation and deletion mutation in *Parp-1*<sup>-/-</sup> mice suggest that Parp-1 may be positively involved imprecise repair pathways which cause base substitution mutation of G:C to A:T and deletion mutation in the brain.

In conclusion, this result supports the view that Parp-1 is involved in suppressing imprecise repair of endogenous DNA damage leading to deletion mutation during aging in the liver and brain. *Parp-1*<sup>-/-</sup> mice show increased incidence of hepatocellular tumors at 18–24 months of ages [13]. The present results suggest a substantial role of Parp-1 in the maintenance of genomic stability and suppression of carcinogenesis during aging.

## Conflict of interest

The authors declare that there are no conflicts of interest.

## Acknowledgements

We are grateful to M. Abe for technical assistance, M. Yanagihara for maintenance of the animals and H. Suzuki and S. Gotoh for helpful suggestions on the manuscript. This work was supported in part by a Grant-in-Aid for the Cancer Research from the Ministry of Health, Labour and Welfare, a Grand-in-Aid from Third Term Comprehensive 10-Year Strategy for Cancer Control, and a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports, and Culture of Japan (16-11804).

## References

- [1] M. Masson, C. Niedergang, V. Schreiber, S. Muller, J. Menissier-de Murcia, G. de Murcia, XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage, *Mol. Cell. Biol.* 18 (1998) 3563–3571.
- [2] C. von Kobbe, J.A. Harrigan, V. Schreiber, P. Stiegler, J. Piotrowski, L. Dawut, V.A. Bohr, Poly(ADP-ribose) polymerase 1 regulates both the exonuclease and helicase activities of the Werner syndrome protein, *Nucleic Acids Res.* 32 (2004) 4003–4014.
- [3] C. von Kobbe, J.A. Harrigan, A. May, P.L. Opresko, L. Dawut, W.H. Cheng, V.A. Bohr, Central role for the Werner syndrome protein/poly(ADP-ribose) polymerase 1 complex in the poly(ADP-ribosyl)ation pathway after DNA damage, *Mol. Cell. Biol.* 23 (2003) 8601–8613.
- [4] S. Galande, T. Kohwi-Shigematsu, Poly(ADP-ribose) polymerase and Ku autoantigen form a complex and synergistically bind to matrix attachment sequences, *J. Biol. Chem.* 274 (1999) 20521–20528.
- [5] B. Li, S. Navarro, N. Kasahara, L. Comai, Identification and biochemical characterization of a Werner's syndrome protein complex with Ku70/80 and poly(ADP-ribose) polymerase-1, *J. Biol. Chem.* 279 (2004) 13659–13667.
- [6] L. Lan, S. Nakajima, Y. Oohata, M. Takao, S. Okano, M. Masutani, S.H. Wilson, A. Yasui, In situ analysis of repair processes for oxidative DNA damage in mammalian cells, *Proc. Natl. Acad. Sci. U.S.A.* 101 (2004) 13738–13743.
- [7] S. Okano, L. Lan, K.W. Caldecott, T. Mori, A. Yasui, Spatial and temporal cellular responses to single-strand breaks in human cells, *Mol. Cell. Biol.* 23 (2003) 3974–3981.
- [8] F. Le Page, V. Schreiber, C. Dherin, G. De Murcia, S. Boiteux, Poly(ADP-ribose) polymerase-1 (PARP-1) is required in murine cell lines for base excision repair of oxidative DNA damage in the absence of DNA polymerase beta, *J. Biol. Chem.* 278 (2003) 18471–18477.
- [9] J.B. Leppard, Z. Dong, Z.B. Mackey, A.E. Tomkinson, Physical and functional interaction between DNA ligase IIIalpha and poly(ADP-Ribose) polymerase 1 in DNA single-strand break repair, *Mol. Cell. Biol.* 23 (2003) 5919–5927.
- [10] M. Tsutsumi, M. Masutani, T. Nozaki, O. Kusuoka, T. Tsujiuchi, H. Nakagama, H. Suzuki, Y. Konishi, T. Sugimura, Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout mice to nitrosamine carcinogenicity, *Carcinogenesis* 22 (2001) 1–3.
- [11] T. Nozaki, H. Fujihara, M. Watanabe, M. Tsutsumi, K. Nakamoto, O. Kusuoka, N. Kamada, H. Suzuki, H. Nakagama, T. Sugimura, M. Masutani, *Parp-1* deficiency implicated in colon and liver tumorigenesis induced by azoxymethane, *Cancer Sci.* 94 (2003) 497–500.
- [12] A. Gunji, A. Uemura, M. Tsutsumi, T. Nozaki, O. Kusuoka, K. Omura, H. Suzuki, H. Nakagama, T. Sugimura, M. Masutani, *Parp-1* deficiency does not increase the frequency of tumors in the oral cavity and esophagus of ICR/129Sv mice by 4-nitroquinoline 1-oxide, a carcinogen producing bulky adducts, *Cancer Lett.* 241 (2005) 87–92.
- [13] W.M. Tong, U. Cortes, M.P. Hande, H. Ohgaki, L.R. Cavalli, P.M. Lansdorp, B.R. Haddad, Z.Q. Wang, Synergistic role of Ku80 and poly(ADP-ribose) polymerase in suppressing chromosomal aberrations and liver cancer formation, *Cancer Res.* 62 (2002) 6990–6996.
- [14] W.M. Tong, U. Cortes, Z.Q. Wang, Poly(ADP-ribose) polymerase: a guardian angel protecting the genome and suppressing tumorigenesis, *Biochim. Biophys. Acta* 1552 (2001) 27–37.
- [15] W.M. Tong, H. Ohgaki, H. Huang, C. Granier, P. Kleihues, Z.Q. Wang, Null mutation of DNA strand break-binding molecule poly(ADP-ribose) polymerase causes medulloblastomas in p53(-/-) mice, *Am. J. Pathol.* 162 (2003) 343–352.
- [16] M.E. Dolle, W.K. Snyder, J.A. Gossen, P.H. Lohman, J. Vijg, Distinct spectra of somatic mutations accumulated with age in mouse heart and small intestine, *Proc. Natl. Acad. Sci. U.S.A.* 97 (2000) 8403–8408.
- [17] K.A. Hill, V.L. Buettner, A. Halangoda, M. Kunishige, S.R. Moore, J. Longmate, W.A. Scaringe, S.S. Sommer, Spontaneous mutation in Big Blue mice from fetus to old age: tissue-specific time courses of mutation frequency but similar mutation types, *Environ. Mol. Mutagen.* 43 (2004) 110–120.
- [18] T. Ono, H. Ikehata, S. Nakamura, Y. Saito, Y. Hosoi, Y. Takai, S. Yamada, J. Onodera, K. Yamamoto, Age-associated increase of spontaneous mutant frequency and

- molecular nature of mutation in newborn and old lacZ-transgenic mouse, *Mutat. Res.* 447 (2000) 165–177.
- [19] M.E. Dolle, H. Giese, C.L. Hopkins, H.J. Martus, J.M. Hausdorff, J. Vijg, Rapid accumulation of genome rearrangements in liver but not in brain of old mice, *Nat. Genet.* 17 (1997) 431–434.
- [20] A. Shibata, N. Kamada, K. Masumura, T. Nohmi, S. Kobayashi, H. Teraoka, H. Nakagama, T. Sugimura, H. Suzuki, M. Masutani, *Parp-1* deficiency causes an increase of deletion mutations and insertions/rearrangements in vivo after treatment with an alkylating agent, *Oncogene* 24 (2005) 1328–1337.
- [21] T. Nohmi, M. Katoh, H. Suzuki, M. Matsui, M. Yamada, M. Watanabe, M. Suzuki, N. Horiya, O. Ueda, T. Shibuya, H. Ikeda, T. Sofuni, A new transgenic mouse mutagenesis test system using Spi- and 6-thioguanine selections, *Environ. Mol. Mutagen.* 28 (1996) 465–470.
- [22] R.R. Swiger, L. Cosentino, K.I. Masumura, T. Nohmi, J.A. Heddle, Further characterization and validation of gpt delta transgenic mice for quantifying somatic mutations in vivo, *Environ. Mol. Mutagen.* 37 (2001) 297–303.
- [23] K. Masumura, K. Kuniya, T. Kurobe, M. Fukuoka, F. Yatagai, T. Nohmi, Heavy-ion-induced mutations in the gpt delta transgenic mouse: comparison of mutation spectra induced by heavy-ion, X-ray, and gamma-ray radiation, *Environ. Mol. Mutagen.* 40 (2002) 207–215.
- [24] K. Masumura, T. Nohmi, Spontaneous mutagenesis in rodents: spontaneous gene mutations identified by neutral reporter genes in gpt delta transgenic mice and rats, *J. Health Sci.* 55 (2009) 40–49.
- [25] K. Masumura, K. Matsui, M. Yamada, M. Horiguchi, K. Ishida, M. Watanabe, O. Ueda, H. Suzuki, Y. Kanke, K.R. Tindall, K. Wakabayashi, T. Sofuni, T. Nohmi, Mutagenicity of 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine (PhIP) in the new gpt delta transgenic mouse, *Cancer Lett.* 143 (1999) 241–244.
- [26] F. Yatagai, T. Kurobe, T. Nohmi, K. Masumura, T. Tsukada, H. Yamaguchi, K. Kasai-Eguchi, N. Fukunishi, Heavy-ion-induced mutations in the gpt delta transgenic mouse: effect of p53 gene knockout, *Environ. Mol. Mutagen.* 40 (2002) 216–225.
- [27] A. Shibata, M. Masutani, T. Nozaki, N. Kamada, H. Fujihara, K. Masumura, H. Nakagama, T. Sugimura, S. Kobayashi, H. Suzuki, T. Nohmi, Improvement of the Spi-assay for mutations in gpt delta mice by including magnesium ions during plaque formation, *Environ. Mol. Mutagen.* 41 (2003) 370–372.
- [28] T. Nohmi, M. Suzuki, K. Masumura, M. Yamada, K. Matsui, O. Ueda, H. Suzuki, M. Katoh, H. Ikeda, T. Sofuni, Spi(-) selection: an efficient method to detect gamma-ray-induced deletions in transgenic mice, *Environ. Mol. Mutagen.* 34 (1999) 9–15.
- [29] A. Shibata, M. Masutani, N. Kamada, K. Masumura, H. Nakagama, S. Kobayashi, H. Teraoka, H. Suzuki, T. Nohmi, Efficient method for mapping and characterizing structures of deletion mutations in gpt delta mice using Southern blot analysis with oligo DNA probes, *Environ. Mol. Mutagen.* 43 (2004) 204–207.
- [30] K. Masumura, M. Matsui, M. Katoh, N. Horiya, O. Ueda, H. Tanabe, M. Yamada, H. Suzuki, T. Sofuni, T. Nohmi, Spectra of gpt mutations in ethylnitrosourea-treated and untreated transgenic mice, *Environ. Mol. Mutagen.* 34 (1999) 1–8.
- [31] H. Kasai, P.F. Crain, Y. Kuchino, S. Nishimura, A. Ootsuyama, H. Tanooka, Formation of 8-hydroxyguanine moiety in cellular DNA by agents producing oxygen radicals and evidence for its repair, *Carcinogenesis* 7 (1986) 1849–1851.
- [32] M.T. Russo, G. De Luca, P. Degan, E. Parlanti, E. Dogliotti, D.E. Barnes, T. Lindahl, H. Yang, J.H. Miller, M. Bignami, Accumulation of the oxidative base lesion 8-hydroxyguanine in DNA of tumor-prone mice defective in both the *Myh* and *Ogg1* DNA glycosylases, *Cancer Res.* 64 (2004) 4411–4414.
- [33] T. Furuta, H. Takemura, Z.Y. Liao, G.J. Aune, C. Redon, O.A. Sedelnikova, D.R. Pilch, E.P. Rogakou, A. Celeste, H.T. Chen, A. Nussenzweig, M.I. Aladjem, W.M. Bonner, Y. Pommier, Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes, *J. Biol. Chem.* 278 (2003) 20303–20312.
- [34] S. Vispe, M.S. Satoh, DNA repair patch-mediated double strand DNA break formation in human cells, *J. Biol. Chem.* 275 (2000) 27386–27392.
- [35] F. Liang, M. Han, P.J. Romanienko, M. Jasin, Homology-directed repair is a major double-strand break repair pathway in mammalian cells, *Proc. Natl. Acad. Sci. U.S.A.* 95 (1998) 5172–5177.
- [36] M. Honma, M. Sakuraba, T. Koizumi, Y. Takashima, H. Sakamoto, M. Hayashi, Non-homologous end-joining for repairing I-SceI-induced DNA double strand breaks in human cells, *DNA Repair (Amst.)* 6 (2007) 781–788.
- [37] Y. Ma, H. Lu, B. Tippin, M.F. Goodman, N. Shimazaki, O. Koiwai, C.L. Hsieh, K. Schwarz, M.R. Lieber, A biochemically defined system for mammalian nonhomologous DNA end joining, *Mol. Cell* 16 (2004) 701–713.
- [38] H. Hohegger, D. Dejsuphong, T. Fukushima, C. Morrison, E. Sonoda, V. Schreiber, G.Y. Zhao, A. Saberi, M. Masutani, N. Adachi, H. Koyama, G. de Murcia, S. Takeda, Parp-1 protects homologous recombination from interference by Ku and Ligase IV in vertebrate cells, *EMBO J.* 25 (2006) 1305–1314.
- [39] M. Wang, W. Wu, W. Wu, B. Rosidi, L. Zhang, H. Wang, G. Iliakis, PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways, *Nucleic Acids Res.* 34 (2006) 6170–6182.
- [40] H. Giese, M.E. Dolle, A. Hezel, H. van Steeg, J. Vijg, Accelerated accumulation of somatic mutations in mice deficient in the nucleotide excision repair gene *XPA*, *Oncogene* 18 (1999) 1257–1260.
- [41] A. de Vries, C.T. van Oostrom, P.M. Dortant, R.B. Beems, C.F. van Kreijl, P.J. Capel, H. van Steeg, Spontaneous liver tumors and benzo[a]pyrene-induced lymphomas in *XPA*-deficient mice, *Mol. Carcinog.* 19 (1997) 46–53.



Contents lists available at ScienceDirect

# Fungal Genetics and Biology

journal homepage: [www.elsevier.com/locate/yfghi](http://www.elsevier.com/locate/yfghi)



## PARP is involved in replicative aging in *Neurospora crassa*

Gregory O. Kothe<sup>a,\*</sup>, Maki Kitamura<sup>b,1,2</sup>, Mitsuko Masutani<sup>c</sup>, Eric U. Selker<sup>a</sup>, Hirokazu Inoue<sup>b</sup>

<sup>a</sup> Institute of Molecular Biology, University of Oregon, Eugene, OR 97403, United States

<sup>b</sup> Lab of Genetics, Department of Regulation Biology, Saitama University, Saitama City 338-8570, Japan

<sup>c</sup> Biochemistry Division, National Cancer Center Research Institute, Tokyo 104-0045, Japan

### ARTICLE INFO

#### Article history:

Received 8 July 2009

Accepted 29 December 2009

Available online xxxx

#### Keywords:

PARP

Aging

*Neurospora*

Chromatin

DNA repair

### ABSTRACT

Modification of proteins by the addition of poly(ADP-ribose) is carried out by poly(ADP-ribose) polymerases (PARPs). PARPs have been implicated in a wide range of biological processes in eukaryotes, but no universal function has been established. A study of the *Aspergillus nidulans* PARP ortholog (PrpA) revealed that the protein is essential and involved in DNA repair, reminiscent of findings using mammalian systems. We found that a *Neurospora* PARP orthologue (NPO) is dispensable for cell survival, DNA repair and epigenetic silencing but that replicative aging of mycelia is accelerated in an *npo* mutant strain. We propose that PARPs may control aging as proposed for Sirtuins, which also consume NAD<sup>+</sup> and function either as mono(ADP-ribose) transferases or protein deacetylases. PARPs may regulate aging by impacting NAD<sup>+</sup>/NAM availability, thereby influencing Sirtuin activity, or they may function in alternative NAD<sup>+</sup>-dependent or NAD<sup>+</sup>-independent aging pathways.

© 2010 Published by Elsevier Inc.

### 1. Introduction

Poly(ADP-ribose) polymerases (PARPs) are ADP-ribose transferases that catalyze the formation of both linear and branched polymers of ADP-ribose (PAR) on target proteins. PAR is covalently linked to the  $\gamma$ -carboxy group of glutamic acid residues at acceptor sites (Burzio et al., 1979; Riquelme et al., 1979). Poly(ADP-ribosylation) (PARYlation) consumes nicotinamide adenine dinucleotide (NAD<sup>+</sup>) and generates nicotinamide (NAM). The addition of PAR to proteins is thought to have dramatic effects on their catalytic activities, as well as on potential protein-protein and protein-nucleic acid interactions (Burkle, 2000; D'Amours et al., 1999; Kraus and Lis, 2003). Recently a number of different proteins have been identified that bind to PAR both *in vitro* and *in vivo*, including proteins containing Macro domains and proteins containing novel poly(ADP-ribose)-binding zinc finger (PBZ) motifs (Ahel et al., 2008; Karras et al., 2005). In higher eukaryotes PARYlation is reversible through the action of PAR glycohydrolases (PARG), which are active in a variety of subcellular compartments, and are thought to be important in regulation of cell death after DNA damage (Ame et al., 2009a,b). Thus, the principle players in PARYlation thus far identified are the PARPs, PARG and PAR binding proteins.

PARP homologs have been identified in plants, metazoans, protists and filamentous fungi, but not in the yeasts, while PARG homologs have been identified in all eukaryotes, excluding fungi. PARPs and PARYlation impact a variety of biological processes including development, transcriptional regulation, chromatin structure, epigenetic phenomena, DNA repair, mitosis, genome stability, neuronal function, cell death and aging (Beneke and Burkle, 2004, 2007; Bouchard et al., 2003; Boulu et al., 2001; Burkle, 2000, 2001a; Burkle et al., 2005; Chiarugi and Moskowitz, 2002; D'Amours et al., 1999; Herceg and Wang, 2001; Hong et al., 2004; Jeggo, 1998; Kim et al., 2005; Kraus and Lis, 2003; Pieper et al., 1999; Smulson et al., 2000).

The canonical PARP enzyme from mammals, PARP-1, has been implicated in both double and single strand break repair (DSB and SSB), as well as base excision repair (BER) (Burkle, 2001b; Dantzer et al., 1999; Masutani et al., 2003). In human and mouse cells, the majority of PARYlation involves auto-modification of PARP-1 in response to DNA damage and PARP-1 has been described as a DNA damage sensor (D'Amours et al., 1999; de Murcia et al., 1997; Huletsky et al., 1989; Ogata et al., 1981). Residual PARYlation is detectable in mouse embryonic fibroblast homozygous for PARP-1 null mutations (PARP-1<sup>-/-</sup>) (Shieh et al., 1998) and this may reflect PARP-2, which has also been shown to PARYlate in response to DNA damage (Ame et al., 1999). Both PARP-1<sup>-/-</sup> and PARP-2<sup>-/-</sup> mice are viable, but are sensitive to DNA damaging agents, and PARP-1<sup>-/-</sup> mice have inherent genomic instability (de Murcia et al., 1997; Menissier de Murcia et al., 2003; Trucco et al., 1998; Wang et al., 1995, 1997). PARP-1<sup>-/-</sup>/PARP-2<sup>-/-</sup> mice die as embryos prior to E8.0, and PARP-1<sup>-/-</sup>/PARP-2<sup>-/-</sup> female mice exhibit

\* Corresponding author. Fax: +1 814 863 7024.

E-mail address: [gok1@psu.edu](mailto:gok1@psu.edu) (G.O. Kothe).

<sup>1</sup> Present address: HOKUTO Co. Nagano 381-0015, Japan.

<sup>2</sup> These authors contributed equally to this work.







208 as Z-sections and analyzed using the program ImageJ. Individual  
209 slices were selected and saved as JPEGs.

210 2.5. Knockout of *npo* by homologous replacement

211 The *npo* gene was amplified by PCR from wild type *N. crassa*  
212 using the following primers: 5'-CAAATGGACGAAAGAGGAGA-3'  
213 and 5'-TGGTCAAAGGAAGGATGAAA-3'. The 6.5 kb PCR product  
214 was digested with *EcoRI* and *SacI*, and cloned into pBluescript  
215 SK+. This construct was then digested with *XhoI* to remove the  
216 *npo* ORF and the hygromycin B-resistant gene (*hph*), derived from  
217 pCB1003 (Carroll et al., 1994), was cloned in its place. The resulting  
218 plasmid (pP1) contains the *hph* gene flanked by 1.9 kb and 1.0 kb of  
219 *npo* upstream and downstream sequences, respectively. To knock-  
220 out the *npo* gene, wild type *N. crassa* (74-OR31-14a) was trans-  
221 formed with an *EcoRI*–*SacI* fragment from pP1. Transformation  
222 was carried out by electroporation as described (Ninomiya et al.,  
223 2004) and hygromycin resistant transformants were crossed to a  
224 wild type *N. crassa* strain of opposite mating type (74-OR31-16A)  
225 to render the integrations homozygous. Finally, *npo* knockout mu-  
226 tants were identified by PCR and Southern hybridization.

227 2.6. Cloning and mutation of *npo* by RIP

228 *npo* was cloned by PCR amplification from wild type *N. crassa*  
229 (N150, 74-OR23-IVA) using the following primers: (2653F) 5'-  
230 TCGAATTCATGCCGCCAGACGAGCAAAG-3'; (2653R) 5'-CTGCGGC  
231 CGTCCATACGCAATGTACTCGTTG-3'. The PCR product was digested  
232 with *EcoRI* and *NotI* and cloned into pBM61 (Margolin et al., 1997)  
233 to generate pGK111. This construct was linearized with *DraI*, and  
234 targeted to the *his-3* locus in strain N1674. Ten transformants were  
235 isolated, and correct integrations were confirmed by Southern  
236 hybridization. Four of the transformants (pGK111-T1, T2, T3, T4)  
237 were crossed with strain N1444 and DNAs from 10 histidine proto-  
238 trophic progeny from each of the four crosses were analyzed for  
239 evidence of mutation of *npo*. Probing of Southern blots of *DpnII*/  
240 *Sau3A* digested DNAs with *npo* sequences revealed RFLPs and hea-  
241 vy methylation in progeny 11 (P11), among others. P11 was ob-  
242 tained from a cross of strain pGK111-T2 with N1444. From here  
243 on this strain is referred to as N3180. The endogenous *npo* gene  
244 was cloned by PCR from strain N3180 using the following primers:  
245 (2653F2) 5'-CTTCACACACATTCACACCTTGTTC-3'; (2653R2) 5'-  
246 GCTATCTTGACACGGAAAAG-3'. Digestion of the PCR product with  
247 *DpnII* confirmed the presence of the RFLPs detected by Southern  
248 blot, and the PCR product was gel isolated and sent for sequencing  
249 using primer 2653F. The *npo* allele present in N3180 is designated  
250 Q3 *npo*<sup>RIP1</sup> (see Table 1).

251 2.7. Testing for genetic interactions between *npo*<sup>RIP1</sup> and *N. crassa*  
252 *Sirtuins* (*nsts*)

253 For the purpose of isolating the *npo*<sup>RIP1</sup> allele in a *mat a* back-  
254 ground, and to look for possible genetic interaction between *npo*  
255 and *nst-1*, N3180 was crossed with N1983 (*mat a*; *mtr col4*; *nst-*  
256 *1*<sup>RIP1</sup> *trp-2*). No obvious defects in growth or development were ob-  
257 served in double mutant progeny. Strain N3181 (*mat a*; *npo*<sup>RIP1</sup>;  
258 *nst-1*<sup>\*</sup>) was obtained from this cross. To isolate *npo*<sup>RIP1</sup> in a back-  
259 ground with a TPE marker and both *nst-1* and *nst-3* mutations,  
260 N3181 was crossed with N2636 (*mat A nst-3*<sup>RIP1</sup>; *mtr col4*; *tel-*  
261 *VR::hph::T*; *nst-1*<sup>RIP1</sup> *trp-2*). Numerous progeny were isolated from  
262 this cross and Southern blots were used to determine their geno-  
263 types. Among the progeny were P6 (*nst-3*<sup>+</sup>; *npo*<sup>+</sup> *telVR::hph::T*;  
264 *nst-1*<sup>\*</sup>), P80 (*nst-3*<sup>+</sup>; *npo*<sup>RIP1</sup> *telVR::hph::T*; *nst-1*<sup>\*</sup>) and P23 (*nst-*  
265 *3*<sup>RIP1</sup>; *npo*<sup>+</sup> *telVR::hph::T*; *nst-1*<sup>\*</sup>) which were tested for TPE (see  
266 Fig. 7) along with others. No obvious defects in growth or develop-  
267 ment were observed for triple mutant progeny.

Table 1  
*Neurospora crassa* strains used in this study.

Strain number	Genotype	Source
N150	<i>mat A</i>	FGSC 2489
N1444	<i>mat a his-3</i> ; <i>am</i> <sup>132</sup>	This study
N1674	<i>mat A his-3</i> ; <i>lys-1 am</i> <sup>132</sup> <i>inl</i> ; <i>am</i> <sup>RIP</sup> :: <i>hph::am</i> <sup>RIP</sup>	Hays et al. (2002)
N1983	<i>mat a</i> ; <i>mtr col4</i> ; <i>nst-1</i> <sup>RIP1</sup> <i>trp-2</i>	This study
N2636	<i>mat A nst-3</i> <sup>RIP1</sup> ; <i>mtr col-4</i> ; <i>telVR::hph::T</i> ; <i>nst-1</i> <sup>RIP1</sup> <i>trp-2</i>	Smith et al. (2008)
N3180	<i>mat A his-3::npo</i> <sup>RIP1</sup> ; <i>am</i> <sup>132</sup> <i>npo</i> <sup>RIP1</sup>	This study
N3181	<i>mat a</i> ; <i>npo</i> <sup>RIP1</sup>	This study
74-OR31-16A	<i>mat A al-2</i> ; <i>pan-2</i> ; <i>cot-1</i>	de Serres (1980)
74-OR31-14a	<i>mat a al-2</i> ; <i>pan-2</i> ; <i>cot-1</i>	de Serres (1980)
MKI-1411A	<i>mat A al-2</i> ; <i>pan-2</i> ; <i>cot-1</i> ; <i>npoKO</i>	This study
MKI-1414a	<i>mat a al-2</i> ; <i>pan-2</i> ; <i>cot-1</i> ; <i>npoKO</i>	This study
14-6-1-1A	<i>mat A al-2</i> ; <i>pan-2</i> ; <i>cot-1</i> ; <i>npoKO</i>	This study
G1	<i>mat A his-3 cyh-1 al-1</i> ; <i>mtr</i> ; <i>inl</i>	FGSC 7508
P49	<i>mat A his-3 cyh-1 al-1</i> ; <i>inl</i>	This study

258 2.8. TPE assays

259 Progeny from the cross of N3181 with N2636 were spot-tested  
260 on hygromycin to assay the effects of mutation of *npo*, *nst-1* and  
261 *nst-3* on TPE in genetic backgrounds with *telVR::hph::T* (Smith et  
262 al., 2008). All possible combinations of alleles were analyzed.  
263 Approximately 1000 conidia were spot-tested on FGS plates con-  
264 taining 600 µg/ml or 1.5 mg/ml hygromycin and supplemented  
265 with alanine, lysine, inositol and anthranilic acid. Spot-tests were  
266 also done on identical plates with no hygromycin as a control for  
267 growth.

268 2.9. Mutagen sensitivity assays

269 For mutagen sensitivity assays, progeny from the cross of  
270 N3181 with N2636 were spot-tested on the same media used in  
271 the TPE assays, but containing either MMS (0.03%), MNNG  
272 (0.5 µg/ml), EMS (0.3%) or CPT (0.3 µg/ml). As with the TPE assay  
273 approximately 1000 conidia were spot-tested, and identical control  
274 plates with no mutagen were used as a control for growth.  
275 Mutagen sensitivity of the *npo* KO strain was tested as previously  
276 described (Watanabe et al., 1997).

269 2.10. PARylation assay

270 Crude *N. crassa* extracts were incubated in 50 mM Tris–HCl (pH  
271 8.0), 10 mM MgCl<sub>2</sub>, 1 mM dithiothreitol, 10 µM (74 KBq/nmol) <sup>32</sup>P-  
272 NAD (Du Pont), 20 µg/ml activated DNA (Sigma) and 20 µg/ml calf  
273 thymus type II-A histones (Sigma H9250) at 25 °C for 30 min. To  
274 stop the reaction, the PARP inhibitor 3-aminobenzamide was  
275 added to 5 mM and unincorporated NAD was removed using spin  
276 columns containing Sephadex G-50 resin (GE Healthcare). *Esche-*  
277 *richia coli* extracts expressing human recombinant PARP-1 (Ikejima  
278 et al., 1990) were used as positive controls. After centrifugation at  
279 300g for 4 min, the eluent containing <sup>32</sup>P-PARYlated proteins was  
280 treated with 0.1 M NaOH at 37 °C for 30 min to detach <sup>32</sup>P-PAR,  
281 and the solution was neutralized by addition of Tris–HCl (pH 7.5)  
282 to 50 mM and HCl to 0.1 N. After extraction with water-saturated  
283 phenol and chloroform–isoamyl alcohol (49:1 (v/v)), ammonium  
284 acetate was added to 2 M and <sup>32</sup>P-PAR was ethanol-precipitated.  
285 After washing with 70% ethanol, the fraction was dried and dis-  
286 solved in a loading dye containing urea (Panzeter and Aithaus,  
287 1990). The fraction was then analyzed by 20% polyacrylamide gel  
288 electrophoresis as described elsewhere (Panzeter and Aithaus,  
289 1990).

1990). The gel was exposed and analyzed with BAS2500 (Fuji Film). The radioactive area containing <sup>32</sup>P-PAR was cut out and further analyzed. The gel fragments were rinsed with water and crushed. The radioactive material was eluted and digested by incubation overnight at 25 °C in 100 µl of a PARC buffer containing 20 mM potassium phosphate (pH 7.5), 10 mM β-mercaptoethanol, 0.05% Triton X-100 (Sigma), 0.1% bovine serum albumin and rat PARC-conjugated with glutathione-S-transferase (GST-PARG) (Shimokawa et al., 1999). Treatment with GST-PARG digested PAR to ADP-ribose, and the reaction mixture was treated with perchloric acid at 0.5 N on ice for 20 min and neutralized with 0.7 M glycyl-glycine-3 M potassium hydroxide and centrifuged at 15,000g for 5 min at 4 °C. The supernatant was subjected to high performance liquid chromatography (HPLC). HPLC was carried out using Develosil columns (C30-UG-5, Ø46X250 mm, Nomura Chemicals). UV absorbance was monitored at 254 nm (Toso, UV-8000). A linear gradient elution for 100 min using buffer A (0.1 M ammonium acetate) and buffer B (50 mM ammonium acetate-50% acetonitrile) was performed, ranging from 2% to 100% buffer B at a flow rate of 0.5 ml/min. The retention time of ADP-ribose was 17-19 min. Each 0.5 ml fraction between 13 and 20 min was concentrated and spotted on DE81 paper (Whatman) and analyzed by BAS2500.

2.11. Telomere erosion assay

Genomic DNAs from wild type and the *npo* strain were digested with *Clal* and *HindIII*. Electrophoresis was carried out in a 2.5% agarose gel for 5 h at 50 mV and Southern blots performed as previously described (Luo et al., 1995; Miao et al., 2000). These blots were then probed with a non-isotopically labeled oligo composed of seven direct tandem copies of the telomere repeat sequence [5'-CCCTAA-3'].

3. Results and discussion

3.1. There are two classes of fungal PARP-like proteins

Semighini et al. (2006) observed that PARP homologs exist in fungi that have multicellular hyphae and sophisticated developmental structures, but lack a prominent yeast-like budding growth

phase. The canonical PARP enzyme from mammals, PARP-1, contains an N-terminal zinc finger DNA-binding domain (zf-PARP), a BRCT motif that is the major target for auto-modification, a WGR motif, and a core catalytic domain (Ame et al., 2004; Kim et al., 2005). We performed TBLASTN searches through the NCBI (http://www.ncbi.nih.gov) fungal genome databases using the human PARP-1 catalytic domain as the query. We then analyzed the hits using the SMART database (http://www.smart.embl-heidelberg.de) to confirm the presence of a PARP catalytic domain (pfam 00644). Our analysis revealed two classes of PARP-like proteins: (1) Homologous to *A. nidulans* PrpA, containing BRCT (pfam 00533) and WGR motifs (pfam 05406) and (2) those with a catalytic domain most similar to mammalian PARP-6/PARP-8 family members and having a carboxyl terminal extension showing homology to the catalytic domain (SMART 00212) of ubiquitin-conjugating enzyme E2 (Fig. 1A). This domain organization seems to be specific to filamentous fungi. We refer to this second class of fungal PARP-like proteins as PARP/E2. Like the PrpA class, the PARP/E2 proteins are broadly distributed in the euascomycetes. In fact, *N. crassa* is the only euascomycete represented in the NCBI fungal genome databases (25 species) that does not have a PARP/E2 homolog, raising the possibility that a *N. crassa* homolog is in a sequencing gap. Homologs in the PARP/E2 class were also found in the basidiomycetes *Coprinus cinereus* (EAF83704.1) and *Phanerochaete chrysosporium* (unannotated protein, contig accession: AADS01000086, gi:46851846, approx. coordinates 71,000-75,000).

3.2. *N. crassa* has a single PARP homolog of the PrpA class

Fungal PARP proteins of the PrpA class lack an amino terminal zinc finger DNA-binding domain (zf-PARP), but have both an N-terminal BRCT motif and a WGR motif (Semighini et al., 2006). A BLASTP search with PARP-1 sequences through the Broad Institute Neurospora genome database (http://www.broad.mit.edu/annotation/genome/neurospora) identified a single ORF encoding a predicted protein of 592 amino acids with a WGR motif, but lacking a BRCT motif (NCU08852.3, EAA31746, GI:157070000, accession AABX02000063.1). We feel that the most likely start codon for this ORF is 235 nucleotides upstream of that suggested by the Broad annotation, which would predict a protein of 670 amino acids with




Fig. 1. Domain organization of fungal PARP-like proteins and associated DNA and PAR binding proteins. (A) Schematic representation of the domain organization of the two classes of fungal PARP proteins. The complete amino acid sequences of NPO. *Neurospora crassa* PARP ortholog [CAD21266] and *Aspergillus nidulans* ANO482.2 [XM\_652294.1] were used as queries to search the SMART database (smart.embl-heidelberg.de). Searching with NPO identified BRCT [IPR001357], WGR [IPR008893], PARP-regulatory [PF02877], and PARP-catalytic [PF00644] domains, defining the PrpA/NPO class. Searching with ANO482.2 identified PARP-catalytic [PF00644] and Ubiquitin-conjugating enzyme E2 catalytic domains [SM00212], defining the PARP/E2 class. (B) Domain organization of the *Neurospora* MacroD protein. The complete amino acid sequence encoded by *Neurospora* ORF NCU07925.3 was used to search the SMART database identifying the A1 pp domain [SM00506]. (C) Domain organization of the *Neurospora* zf-PARP protein. The complete amino acid sequence of a *Neurospora* hypothetical protein [Broad coordinates LG1, containing 2:447973 – 449833+] was used to search the SMART database identifying a single zf-PARP Pfam domain [PF00645].

380 both WGR and BRCT motifs, as expected for a member of the PrpA  
381 class (Fig. 1A). We refer to this protein as *Neurospora* PARP Ortho-  
382 log (NPO). The presence of BRCT motifs in the PrpA class of fungal  
383 PARPs, and their absence from PARP-2 homologs, suggests that  
384 proteins of the PrpA class are more closely related to PARP-1. How-  
385 ever, comparison of NPO with human PARP-1 and PARP-2 using the  
386 BL2SEQ program suggests a closer relationship with PARP-2 [NPO:-  
387 PARP-1,  $e = 10^{-79}$ , identities = 216/681 (31%), similarities = 335/  
388 681 (49%), gaps = 67/681 (9%); NPO:PARP-2,  $e = 3 \times 10^{-82}$ , identi-  
389 ties = 187/464 (40%), similarities = 259/464 (55%), gaps = 39/464  
390 (8%)]. In agreement with our analysis Semighini et al. (2006) ob-  
391 served that PrpA-like PARPs belong to a microbial clade more sim-  
392 ilar to PARP-2 than PARP-1.

393 3.3. Fungal zf-PARP proteins, macro domain proteins and nuclear  
394 localization of NPO

395 Fungal PARP-like proteins, including NPO, lack any obvious  
396 DNA-binding domain, raising the question of whether these pro-  
397 teins are principally associated with chromatin, like their meta-  
398 zoan counterparts. NPO might contain a cryptic DNA-binding  
399 domain or could require a partner for DNA binding. Because  
400 PARP-1 contains a highly characteristic amino terminal zinc finger  
401 DNA-binding domain (zf-PARP), we sought to identify fungal pro-  
402 teins containing a similar motif. To this end we performed  
403 TBLASTN searches through the NCBI fungal genome database  
404 using the PARP-1 zinc finger as query. These searches identified  
405 a single *Neurospora* ORF encoding a protein of 404 amino acids,  
406 containing a single zinc finger of the zf-PARP class (Fig. 1B). We  
407 refer to this protein as ZFP. Although this ORF has not been anno-  
408 tated with an NCU number in the Broad database, we believe that  
409 it represents a functional gene, as a GFP tagged form, expressed  
410 via its own promoter, has a punctate nuclear staining pattern,  
411 similar to the heterochromatin associated protein, HP1 (Fig. 2)  
412 (Freitag et al., 2004a). To determine the subcellular location of  
413 NPO we tagged the protein with GFP at its carboxyl terminus,  
414 and expressed the fusion protein in aerial hyphae and conidia  
415 using the developmentally regulated *cgg-1* promoter (Fig. 2) (Fre-  
416 itag et al., 2004b; Loros et al., 1989; McNally and Free, 1988). GFP  
417 tagging of ectopically expressed NPO verifies that this protein is  
418 also localized primarily to nuclei (Fig. 2), and thus has a func-  
419 tional nuclear localization signal. The subnuclear distribution of  
420 NPO seems to be essentially uniform, in comparison to proteins

421 localized specifically to heterochromatin (HP1), telomeres  
422 (RAP1) and rDNA (YPH1) (Fig. 2).

423 We have not been able to identify any PARG-like protein in any  
424 filamentous fungal database, and thus PAR may be a more stable  
425 posttranslational modification in fungi than in higher eukaryotes.  
426 Although we were unable to identify fungal proteins with the  
427 PAR-binding C2H2 zinc finger (PBZ) domain (Ahel et al., 2008),  
428 we did identify one ORF encoding a protein of 277 amino acids  
429 with a single Macrodomain (also designated as A1 pp) (Fig. 1C).  
430 Macrodomains have also been shown to bind PAR both *in vivo*  
431 and *in vitro* (Karras et al., 2005). The *Neurospora* Macrodomain  
432 protein is annotated in the Broad database as NCU07925.3, and  
433 we refer to it as Macrodomain (MCD). An over-expressed GFP  
434 tagged form of MCD has essentially uniform cytoplasmic and nu-  
435 clear distributions, but is slightly more concentrated in nuclei than  
436 in cytoplasm (Fig. 2). Thus, while NPO has an autonomous nuclear  
437 localization signal, it may be brought to DNA via association with  
438 other proteins such as ZFP. Furthermore, while fungi are unlikely  
439 to remove PAR via a glycohydrolase activity, as mammals do, they  
440 are likely to recognize PAR via nuclear localized Macrodomain pro-  
441 teins such as MCD.

442 3.4. *npo* is a nonessential gene in *N. crassa*

443 After verifying the nuclear distribution of NPO we then isolated  
444 *N. crassa* stains with mutations in the *npo* gene using Repeat In-  
445 duced Point mutation (RIP) (Seiker, 1990) and made knockout  
446 strains by replacing the *npo* coding sequence with the bacterial  
447 hygromycin phosphotransferase gene (*hph*) (Figs. 3 and 4A and  
448 B). Both homozygous and heterozygous crosses of strains carrying  
449 duplications of *npo* at the *his-3* locus were fully fertile. These re-  
450 sults suggest that *npo* is not required in the brief diploid phase  
451 for completion of meiosis, as heterozygous duplications would be  
452 expected to trigger meiotic silencing by unpaired DNA (MSUD)  
453 (Aramayo and Metzberg, 1996; Shiu et al., 2001). However, it  
454 is also possible that there is enough transcript or protein present  
455 in ascogenous hyphae to override the effect of MSUD during the  
456 diploid phase.

457 We confirmed the presence of mutations by RIP in progeny  
458 from these crosses by Southern hybridization and DNA sequenc-  
459 ing. Clear evidence of RIP was detected by Southern hybridization  
460 in 6 out of 40 progeny. None of the six progeny exhibited any  
461 gross morphological or developmental phenotypes. Sequencing




Fig. 2. Confocal images of GFP-tagged *Neurospora* proteins. Expression of heterochromatin protein 1 (HP1::GFP), a telomere repeat binding protein (RAP1::GFP), MacroD::GFP and NPO::GFP was driven by the *cgg-1* promoter. An rDNA associated protein (YPH1::GFP) and zf-PARP::GFP were expressed via their endogenous promoters.

Please cite this article in press as: Kothe, G.O., et al. PARP is involved in replicative aging in *Neurospora crassa*. Fungal Genet. Biol. (2010), doi:10.1016/j.fgb.2009.12.012

```

1 AATCTTGACACGGTCGTGGAGTGAGTGCCTGTCTCACCCCTTCTTCTACTTCCACGCC 60
61 CCATTGTTTGTACTTTCGGACGGCCCTTCACACACTTCACACCTTGTTCCTCCTGA 120
121 GACCCCATCAGTTCGTGCGGATGCCGCCAGCAGGCAAGAAGGAGCGGCTGCCCCAG 180
1 C P P R R A K K E A A A P A 184
181 CCAAACCTCCGCTGAAGACTGTCCGATGTCTTTAGCGGAACCTTTGTGGCGGTCAG 240
15 K L P L E D C R I V F S G T F V G G Q D 34
241 ACCAGCACAAAGAAACAGCAGATCCCTCGGAGCAAACACCACGGGACTACCATCGTTC 300
35 Q H K K T A E S L G A N T F G T T I V Q 54
301 AGAGCGTCACCCATTAATCTACTCGGACAAGGACCCGACAAATAAGCGCCAAAGTCA 360
55 S V T H V I Y S D K S T D K I S A K V R 74
361 AGCAGGCACACGAATGAGCATCCCGTTGTGAGCATTTGACTGGCTGCTGAAGCAAAG 420
75 Q A H G H S I P V V S I D W L E K T K E 94
421 AGACCAACACCCGACATCCTAGAGGATTACCTCTGACTTGTCTCTTTGGATGCCG 480
95 T N T R H P E K D Y A L D L S S L D A A 114
481 CAAGCGACACCTCTGTGGCTACCGCAGATACTACCTCCAGACCAACGGCGATGACACCA 540
115 S D T S V A G A D A D T T S Q T N G D D T R 134
541 GAGGCCAACAGAAAGAGATCGCCGTCGCCCTGCCAGGATGGCCCAAGGCTCATGGTG 600
135 G T K R K R S P S P A Q D G A K A D G E 154
601 AGGAGGAGCACACTCTGAAAAGTCCAAACTCGAAACCAAAAGGGCCATGGGGCAGGGCC 660
155 E E D T L K R S K L E T K R A H G E G Q 174
661 AAATCTGAAGGACAGACTGTGCAGATCCCTGTGACGCCGGCGCTCCATATGGCTTCG 720
175 I L K D K T V Q I P V D A G A P Y G F A 194
721 CCGTTCATTTGATTCTATGGTgttatttatcagcattcatttaacctgaccaattcca 780
195 V H V D S D G 201
781 ctgcaacaacaacaagtctctctcagggcaactcaccgctcacaacgctcgctctct

841 gcacccccagactaactcatcaaatagCTTCTACGCACTCGAGCGGCTCTGCGCTGTC 900
202 L L T Q S S G W C A V 212
901 TGGACCGCTGGGGCGTGTCCGGAAGATCCGGCCAGCAGCGGCTCATTAATGCCAGTCT 960
213 M T R W G R V G E S G O H A L I D C Q S 232
961 CTCGAAGATGCCCTGCAAACTTTGAAAAGAAGTCAAGGACAAGTCGGGATTCCTCG 1020
233 L Q D A L O T F E K K F K D K S G L L W 252
1021 AGCAACCGAGGTGATAACCCCAAGCCCAAGAAGTATGCCCTTCGTCGAGGTAACATAAG 1080
253 S N R G D N P K P K K Y A F V E V N Y K 272
1081 GATGAATCCGATCAGCAAGAGGAGCGGAGGCGCCGCCACGAAAGAGAAAGAG 1140

```

Fig. 3. Sequence of the *npo<sup>RIP1</sup>* allele. The NPO protein sequence is indicated beneath the upper case nucleotide coding sequence. Lower case nucleotides represent intron sequences. The boxed amino acid in the first exon indicate the BRCT domain and the boxed amino acids in the second exon indicate the WGR motif. Guanine residues mutated to adenines are highlighted, and the tryptophan codon that was mutated to a stop codon is boxed. The sequence of the *npo<sup>RIP1</sup>* allele had been deposited in Genbank with the accession number EU869543.

of a PCR product amplified from progeny number 11 (P11) identified 21 C:G to T:A transition mutations in a 591 base pair segment of the endogenous *npo* gene (Fig. 2). All G to A mutations were found on the coding strand, spanning the first and second exons. The 21 mutations affected 15 codons, with five mutations occurring in the intron. Of the 16 mutation occurring in codons, four were in 3rd position and silent (V53, L106, L203 and Q205), seven were in 1st position, resulting in conservative substitutions (V59 → I, E101 → K, D121 → N, D152 → N, V181 → M, V197 → I and D200 → N), two were in 1st position resulting in nonconservative substitutions (G78 → R and A105 → T) and one was in second position producing a stop codon (W209 → stop). The conservative substitution at position 185 (V185 → I) resulted from G to A transitions in both the 1st and 3rd positions. The introduction of a stop codon at W209 is very likely to eliminate NPO function, as it occurs in the amino terminal region of the WGR motif, upstream of the PARP catalytic domain (Fig. 3). We refer to this allele as *npo<sup>RIP1</sup>* and the original progeny harboring the allele (P11) as N3180.

All tested strains carrying *npo<sup>RIP1</sup>* were fully fertile as males or females, and homozygous crosses appeared normal as well. Knockouts of *npo* were made by homologous replacement of the *npo* coding region with *hph* in a wild type background. Proper replacements were confirmed by PCR analysis and Southern blots (Fig. 4A and B). Strains with the *npo* KO, like strains with the *npo<sup>RIP1</sup>* allele, did not exhibit gross morphological or developmental phenotypes, and were fully fertile in heterozygous and homozygous crosses. We conclude that *npo* is a nonessential gene in *N. crassa* and is not required for normal growth or development. These results stand in contrast to what was reported for a *prpA* knockout in *Aspergillus*, which was lethal in haploid strains, and produced severe growth restrictions and developmental phenotypes in heterozygous diploid

strains ( $\Delta prpA/+$ ), described as haplo-insufficient (Semighini et al., 2006).

### 3.5. NPO is a PAR-polymerase

We assayed PARylation activity in extracts from both wild type and *npo* KO strains to determine if NPO functions as a protein PAR-polymerase. To our knowledge, results from PARylation assays have only been reported for mammalian systems. To assay PARylation, crude extracts from wild type and the *npo* KO strain were prepared from conidia that had either been treated or not treated with MMS for 60 min. The crude extracts were incubated with <sup>32</sup>P-NAD, sheared DNA and histones. As a positive control, an assay was also performed on extracts from *E. coli* cells expressing recombinant human PARP-1. PAR was detached from proteins by alkaline treatment and analyzed on 20% PAGE. As shown in Fig. 5A, the MMS-treated wild type strain produced a PAR-ladder like the human PARP-1 control (right-most lane), but the *npo* KO strain did not. To confirm that the ladder observed with the MMS-treated wild type strain reflected PAR, the radioactive material was eluted from the gel, digested with PAR-glycohydrolase (PARG), which specifically cleaves PAR into ADP-ribose, and analyzed by HPLC. As shown in Fig. 5B, the radioactivity that eluted at the retention time of ADP-ribose, namely at 18–19 min, is higher in the PARG-treated sample than in the untreated control. It is possible that the radioactivity detected at 18–19 min in the PARG untreated control is due to degradation of PAR to ADP-ribose during PARG-treatment or due to unrelated products generated during the <sup>32</sup>P-NAD incorporation reaction. The control extract containing human PARP-1 also showed high intensity spots at 18–19 min, corresponding to ADP-ribose. We conclude that *N. crassa* PARylation increases in response to MMS treatment, and that this activity depends on NPO, which is likely responsible for most or all PARylation in *N. crassa*.




Fig. 4. Disruption of the *N. crassa npo* gene by homologous recombination. (A) Schematic illustration of knockout strategy for the *npo* gene and shows the direction of transcription. Stippled boxes indicate immediate flanking sequences. The knockout construct is shown below the genomic sequence with the *E. coli hph* gene represented by a black box. The genomic sequence resulting from correct replacement is shown beneath the knockout construct. Horizontal black arrows indicate the positions of PCR primers used to analyze the transformants. Vertical black arrows indicate restriction sites used to characterize the transformants by Southern hybridization. A horizontal black line represents the probe used in the Southern blot. (B) The images labeled PCR6 and PCR7 are ethidium bromide-stained agarose gels with size markers run in the left-most lanes. The next three lanes contained PCR products that had been amplified from wild type *N. crassa* DNA, as controls. The position of primers for the PCR6 and PCR7 reactions are shown in panel A. The right-most image shows an autoradiograph of a Southern blot probed with *hph* sequences. DNAs from the indicated transformants were digested with *Nco*I. DNA from wild type *N. crassa* was run in the right-most lane as a control.

526 3.6. *npo* transcription is induced by MMS treatment

527 It is well established that auto-modification of mammalian  
528 PARP-1 increases dramatically with the binding of the protein to  
529 double and single-strand DNA breaks. Although the transcriptional  
530 response of the mammalian PARP-1 gene to DNA damaging agents  
531 has not been reported, plant PARP-1 and PARP-2 gene transcription  
532 is highly induced by DNA damage (Doucet-Chabeaud et al., 2001).  
533 In addition, Semighini et al. (2006) found *prpA* steady-state trans-  
534 cript levels increased in response to MMS, BLM and 4-NQO treat-  
535 ments. Our results from PARylation assays demonstrated a  
536 dramatic increase in NPO activity in response to MMS treatment.  
537 To determine if this reflected a change in *npo* transcript levels or  
538 enzyme activity, we performed Northern blots of RNAs isolated  
539 from wild type and *npo* KO strains that had either been treated  
540 or not treated with MMS. The blots were probed with *npo* se-  
541 quences, and *cox-5* sequences as a control for the loading. In un-  
542 treated wild type cells, *npo* transcripts were undetectable by  
543 Northern blot, but a large accumulation of *npo* transcript was de-  
544 tected 30 min after treatment of wild type cells with MMS, and  
545 high levels of transcript were still detectable 120 min after treat-  
546 ment (Fig. 6). As expected, no *npo* transcripts were detectable in  
547 the *npo* KO strain (Fig. 6). Thus *npo* transcription is likely to be reg-  
548 ulated in response to DNA damage, like the *A. nidulans prpA* gene.

527 3.7. *npo* mutant strains are not sensitive to DNA damaging agents

528 Genetic and biochemical studies of mammals established roles  
529 for PARP-1 in DNA repair and genome stability (Masutani et al.,  
530 2003; Watanabe et al., 2004). The fact that the steady-state trans-  
531 cript levels of *npo* were regulated by exposure to MMS suggested  
532 that NPO may play a role in a DNA damage response. We tested the  
533 effects of a number of DNA damaging agents on *N. crassa* strains  
534 carrying either the *npo*<sup>RIP1</sup> allele or the *npo* KO. We tested CPT,  
535 EMS, H<sub>2</sub>O<sub>2</sub>, HU, MMS, MNNG and UV (Fig. 7), as well as BLM (data  
536 not shown). Neither mutant showed sensitivity to any of these  
537 compounds. Semighini et al. (2006) found the haplo-insufficient  
538  $\Delta prpA/+$  mutant to be extremely sensitive to both phleomycin  
539 (PLM), which induces double-strand breaks, and the UV-mimetic  
540 agent 4-NQO. While we did not test PLM, the *npo* mutants were  
541 not sensitive to BLM, which also induces DNA double-strand  
542 breaks (Povirk et al., 1977). Because *npo* transcript levels increase  
543 in response to MMS, it is likely that NPO function is connected with  
544 a DNA damage response. The fact that *npo* mutants are not sensi-  
545 tive to DNA damaging agents suggests the function may be redun-  
546 dant, or it may impact a nonessential aspect of repair.  
547 Alternatively, NPO may function in related processes such as regu-  
548 lating expression of genes controlled by DNA damage. The fact that  
549 *A. nidulans PrpA* is necessary for normal repair reveals divergence






Fig. 5. Verification of NPO PARylation activity. (A) Autoradiogram of a 20% poly acrylamide gel showing <sup>32</sup>p-PAR ladder. PARylation reactions with extracts from wild type *N. crassa* cells treated (+) or not treated (-) with MMS were run alongside reactions with extracts from *npo* KO cells treated (+) or not treated (-) with MMS. The lane labeled DW is a negative control reaction using distilled water in place of extract. The right-most lane contains a positive control reaction with recombinant human PARP-1 expressed in *E. coli*. The boxed regions labeled a and b were excised and the radioactivity was eluted for analysis by HPLC. (B) An autoradiogram (BAS2500) of fractions from HPLC blotted onto DE81 paper (Whatman) with retention times indicated above and sample designations on the left. Eluents of <sup>32</sup>p-PAR from these gel slices were either treated with recombinant PARG, or not, and fractionated by HPLC as described in Section 2. The boxed regions show the peak signals eluted at the retention time for ADP-ribose.




Fig. 6. Analysis of *npo* transcription by Northern blot. The left panel shows an autoradiogram of a northern blot of RNAs extracted from wild type *N. crassa* after the indicated duration of MMS treatment. The upper panel shows results of probing the blot with *npo* sequences and in the lower panel shows results of probing with *cox-5* sequences as a control for loading. The right panel shows the same for the *npo* strain.

effects, such as Telomere Position Effect (TPE), are lacking. We recently developed *N. crassa* strains with markers at subtelomeric positions to examine TPE (Smith et al., 2008). This system allowed us to identify factors that control TPE, including several Sirtuins, termed Neurospora Sirtuins (NSTs). To analyze the effect of mutations in *npo* on TPE, we crossed the *npo*<sup>RIP1</sup> allele into a background with the *E. coli hph* gene targeted to telomere VR (*telVR::hph::T*). We found significant derepression of *hph* at telomere VR in a strain with mutations in the *N. crassa* Sirtuin gene *nst-3* (*nst-3*<sup>RIP1</sup>), but not in a strain with *npo*<sup>RIP1</sup> (Fig. 8).

3.9. NPO is not involved in DNA methylation or DNA methylation-dependent silencing

In mammals it has been reported that PARP-1 is antagonistic to DNA methylation. Treatment of mouse fibroblasts with the competitive PARP inhibitor 3-aminobenzamide (3-AB) resulted in DNA hypermethylation and PAR has been shown to inhibit the activity of the maintenance DNA methylase, DNMT1 (Reale et al., 2005). *N. crassa* is the simplest genetically tractable system used to study DNA methylation. In *N. crassa* virtually all DNA methylation occurs in transposons that have been mutated by RIP (Selker et al., 2003) and this methylation is not confined to symmetrical positions (Selker et al., 1993). Numerous viable *N. crassa* mutants with reduced methylation have been described, including *dim-2*,

in DNA damage response pathways between *Neurospora* and *Aspergillus*.

3.8. NPO is not a global regulator of TPE

In metazoans, PARP enzymes are involved in chromatin-mediated regulation of transcription (Krishnakumar et al., 2008). Although considerable progress has been made in understanding the role of PARPs in regulating chromatin structure, simple genetic studies to test their possible involvement in epigenetic position




Fig. 7. Mutagen sensitivity of the *npo* KO strain. Spot-tests of conidia on FGS plates for wild type *N. crassa* (top), the *npo* (middle) and *mei-3* strains (bottom) were done as described in Section 2. The *mei-3* strain was used as a positive control for mutagen sensitivity. Panels from left to right are as follows: no mutagen; 0.015% methyl methane sulfonate (MMS); conidia pretreated with 450 J/MF UV; 30 mM hydroxy urea (HU); 0.05 µg/ml N-methyl-N'-nitro-N-nirtosoguanidine (MNNG); 0.3% ethyl methane sulfonate (EMS); 0.3 µg/ml camptothecin (CPT) and 0.0015% H<sub>2</sub>O<sub>2</sub>.




Fig. 8. Telomere position effect assay. Spot-tests of conidia on FGS plates for wild type *N. crassa*, *npo*<sup>RIP1</sup>, and *nst-3*<sup>RIP1</sup> strains on media with 1.5 mg/ml hygromycin or no hygromycin, as described in Section 2.




Fig. 9. Absence of effects of NAM treatment and *npo* mutation on DNA methylation. (A) Approximately 1 µg samples of chromosomal DNA, isolated from wild type *N. crassa* (N150) grown for 3 days in Vogles minimal media with the indicated concentrations of NAM, were digested either with *DpnII* (D) or *Sau3A* (S) and fractionated on a 1X TAE/0.8% agarose gel containing 1 µg/ml ethidium bromide. The left-most lane contains 0.5 µg of 1 kb DNA ladder (Invitrogen). (B) A Southern blot of chromosomal DNAs from wild type and *npo* mutant strains digested with *DpnII* (D) or *Sau3A* (S), as described for panel A and in Section 2. The Southern blot was probed with ψ63 sequences.

603 *dim-5*, and *hpo*. Mutation in any of these genes completely abolishes all detectable DNA methylation (Freitag et al., 2004a; 604 Kouzminova and Selker, 2001; Tamaru and Selker, 2001). Although 605 no mutants with hypermethylation have been described in *N. crassa* 606 thus far, strains of *Ascobolus immersus* carrying silenced copies of 607 the histone H1 gene (*hH1*) were shown to have elevated levels of 608 DNA methylation (Barra et al., 2000). This hypermethylated DNA 609 could be detected globally on ethidium bromide-stained agarose 610 gels, as higher molecular weight fragments after digestion with 611 methylation sensitive restriction enzymes.

612 As a first test of whether inhibition of NPO effects DNA methylation 613 we treated wild type *N. crassa* cells with high concentrations of 614 nicotinamide (NAM) and looked at global DNA methylation by 615 analyzing *Sau3A*- and *DpnII*-digested DNAs on agarose gels 616 (Fig. 9A). NAM acts as a strong noncompetitive inhibitor of both 617 Sirtuins and PARPs, and we had previously shown that treatment 618 of *N. crassa* with NAM dramatically reduces silencing of *telVR::hph*, 619 but has no effect on silencing of the methylated transgene *am*<sup>RIP</sup>::*hph* 620 (*am*<sup>RIP</sup>::*hph*::*am*<sup>RIP</sup>) (Smith et al., 2008). No effect on global DNA methylation 621 was observed after NAM treatment (Fig. 9A). The fact that NAM 622 treatment did not relieve silencing of *am*<sup>RIP</sup>::*hph*::*am*<sup>RIP</sup>, suggests 623 that neither NPO nor NSTs are involved in methylation-dependent 624 silencing at this locus. Because it was conceivable that NPO is 625 resistant to NAM, we also tested if mutation of *npo* would affect DNA 626 methylation. Southern blots of *Sau3A*- and *DpnII*-digested DNAs 627 from progeny with mutations by RIP in the *npo* gene, including 628 strain P11, which is likely to be a null mutant, revealed heavy 629 DNA methylation when probed with *npo* sequences (data not 630 shown). We probed the same Southern blots with ψ63 sequences, 631 which are normally methylated (Margolin et al., 1998), and did not 632 see any change in DNA methylation at this locus (Fig. 9B). We also 633 looked at global DNA methylation levels by ethidium bromide 634 staining in *N. crassa* strains with the *npo*<sup>RIP1</sup> allele and saw no effect 635 (data not shown). In addition, presence of the *npo*<sup>RIP1</sup> allele, or 636 quelling experiments with *npo* sequences, had no effect on silencing 637 of *am*<sup>RIP</sup>::*hph*::*am*<sup>RIP</sup> (data not shown), indicating that NPO is 638 not involved in methylation-dependent silencing. We conclude 639 that *npo* is not involved in DNA methylation. 640

641 3.10. The *npo* knockout causes acceleration of replicative aging

642 Studies of aging in filamentous fungi have focused largely on 643 replicative aging associated with mitochondrial DNA (mtDNA) 644 rearrangements triggered by mitochondrial plasmid/intron

645 mobilizations (Osiewacz, 2002). Replicative lifespan is a measure 646 of the number of mitotic divisions a cell undergoes before senescence. 647 Analogous to the ERC situation in yeast, these mechanisms seem to be 648 specific to filamentous fungi. Barra et al. (2000) reported that 649 strains of *A. immersus* with silenced copies of the *hH1* gene 650 exhibited a decreased replicative lifespan, along with DNA 651 hypermethylation. Such strains were found to initiate 652 growth normally, but to senesce between 6 and 13 days after germination, 653 whereas strains with unsilenced *hH1* continued with a linear rate of 654 growth for up to 40 days. We observed a similar phenotype for our 655 *npo* KO strain, although the replicative lifespan of *N. crassa* 656 mycelia is considerably longer than that of *A. immersus* (500 days 657 versus 35–40 days, respectively). We grew both wild type and 658 *npo* KO strains on minimal medium in 30 cm race tubes at 34 °C with 659 12 h dark/light cycles, and were careful to transfer only mycelial 660 fragments upon inoculation (Fig. 10A). The *npo* KO strain had a 661 linear growth rate indistinguishable from wild type for the first 140 662 days of growth (6 cm/day), at which point the growth rate started 663 to decrease gradually, culminating in senescence at around 300 664 days (Fig. 10B).

665 3.11. Telomere erosion does not occur in the *npo* knockout strain

666 Eukaryotic microorganisms must maintain telomere length in 667 every proliferating cell type, either by telomerase activity or by 668 recombination. We were therefore interested to test if the increased 669 replicative aging observed in the *npo* strain reflected defective 670 maintenance of telomeres. To determine if mutation of *npo* affects 671 telomere length in *N. crassa*, DNA was isolated from young 672 cultures (~80 h) and old cultures (~8000 h) of both wild type and 673 *npo* KO strains. The DNAs were digested with *Clal* and *HindIII* and 674 Southern blots were probed with telomere repeat sequences. The 675 8000 h time point was chosen because this is when the *npo* KO 676 strain begins to senesce (Fig. 11A). The Southern blots did not 677 reveal any obvious change in the length of the *npo* KO telomeres, 678 even after 8000 h of culture time (Fig. 11B). Therefore, regulation 679 of telomere length does not appear to be a factor in lifespan reduction 680 for the *npo* KO strain.






Fig. 10. Method and results of senescence assay. (A) Schematic of race tube strategy for measuring long-term linear extension rate. (B) Plot of growth (cm/h) for wild type *N. crassa* and *npo* strain. Arrows at 3400 h and 12,000 h indicate entry into senescence for *npo* and wild type *N. crassa* strains, respectively.




Fig. 11. Telomere stability in wild type and *npo* mutant strains. (A) Arrows on plot shows time points used in telomere erosion assay. (B) Chromosomal DNAs were isolated from wild type and the *npo* mutant at the time points indicated in panel A. The DNAs were digested with *Hae*III, blotted as described in Section 2, and probed with telomere repeat sequences.

681 3.12. PARylation is not universally required for viability or DNA repair

682 PARP orthologs have been identified in all eukaryotes, excluding  
683 yeast. Both plants and animals typically have multiple PARP ortho-  
684 logs, making genetic characterization difficult. Lethality of PARP-  
685 1<sup>-/-</sup>/PARP-2<sup>-/-</sup> mice and evidence linking PARylation with DNA  
686 repair and genomic stability support a view that PARylation im-  
687 pacts nuclear functions essential for higher eukaryotic develop-  
688 ment or survival. Unsuccessful attempts to generate PARP-1/  
689 PARP-2 double knockouts in mouse embryonic fibroblasts (Med-  
690 er et al., 2005) suggest that these functions may be critical for cellular  
691 survival. Mutation of dPARP in *Drosophila* results in larval lethality  
692 at the second instar stage, with disruption of heterochromatin  
693 organization and elimination of nucleoli (Tulin et al., 2002), again  
694 supporting the hypothesis that PARPs provide nuclear functions  
695 essential to the cell. Recent work on PARP in the filamentous fun-  
696 gus *A. nidulans* extends this view to PARylating lower eukaryotes

(Semighini et al., 2006). Our work in *N. crassa* stands in contrast  
697 to what has been found for mammals and *A. nidulans*, as *N. crassa*  
698 *npo* mutants are viable and do not show sensitivity to mutagens,  
699 establishing that PARylation is dispensable for both viability and  
700 DNA-repair in certain eukaryotes with PARP orthologs. The fact  
701 that transcription of PARP genes is induced by DNA damage in both  
702 plants (Doucet-Chabeaud et al., 2001) and filamentous fungi  
703 (Semighini et al., 2006) does support the idea that there is a univer-  
704 sal function for PARylation in DNA repair, but this function may be  
705 redundant in *N. crassa*, but not *A. nidulans*.  
706

3.13. PARylation is not required for heterochromatin formation in *N. crassa*

707  
708  
709 Two major heterochromatin silencing pathways described in *N.*  
710 *crassa* are TPE (Smith et al., 2008) and cytosine methylation (Selker,  
711 2004). Our analysis indicates that neither pathway is significantly

712 affected by mutation of *npo*. The histone H3 K9 methylase, DIM-5  
713 (Tamaru and Selker, 2001), and the HP1 ortholog, HPO (Freitag et  
714 al., 2004a), are necessary for silencing at all tested *N. crassa* telo-  
715 meres (Smith et al., 2008), as well as for all detectable DNA meth-  
716 ylation. It is formally possible, however, that NPO might regulate  
717 TPE at telomeres other than VR or DNA methylation at a subset  
718 of unanalyzed genomic loci, although we have no reason to expect  
719 this to be so. We have shown that treatment of *N. crassa* with NAM  
720 dramatically reduces silencing of *telVR::hph*, but has no effect on  
721 silencing of the methylated transgene *am<sup>RIP</sup>::hph::am<sup>RIP</sup>*. Before  
722 our analysis of the effect of the *npo<sup>RIP1</sup>* allele on silencing of *tel-*  
723 *VR::hph*, we could not fully interpret these data. Our genetic studies  
724 now suggest that the mechanism of action of NAM on TPE involves  
725 inhibition of NSTs, but not NPO. The fact that NAM treatment did  
726 not relieve silencing of *am<sup>RIP</sup>::hph::am<sup>RIP</sup>*, strongly suggests that  
727 neither NPO nor NSTs are involved in methylation or methyl-  
728 ation-dependent silencing at this locus. The observation that  
729 PARP-1 activity impacts DNA methylation in mammals implies  
730 divergence in pathways that regulate methylation between mam-  
731 mals and filamentous fungi. This is not surprising considering that  
732 the activity of DNMT1, which is the primary maintenance methyl-  
733 ase in mammals, is inhibited by PAR (Reale et al., 2005). *N. crassa*  
734 lacks this form of maintenance methylation, which acts specifically  
735 on hemimethylated CpG dinucleotides in conjunction with DNA  
736 replication. In *N. crassa*, both maintenance and *de novo* methylation  
737 are carried out by a single methyltransferase, DIM-2 (Kouzminova  
738 and Selker, 2001), which does not require a symmetrical sequence  
739 (Selker et al., 1993). It would be interesting to know whether PARP  
740 inhibitors or silencing of a PARP ortholog affect DNA methylation  
741 in *A. immersus*, as this species may have a maintenance methyl-  
742 ation system that is more similar to that in mammals.

### 743 3.14. The NPO aging pathway does not involve telomere length 744 maintenance

745 Some current models for regulation of aging in humans consider  
746 telomere maintenance potentially important, as somatic human  
747 cells lack telomerase activity, and thus have a finite replicative life-  
748 span (Campisi, 2005; Verdun and Karlseder, 2007). Recently, SIRT6  
749 has been shown to function as a telomere-specific histone H3 K9  
750 deacetylase, which is necessary for normal telomere maintenance  
751 and for prevention of premature cellular senescence in human  
752 fibroblasts (Michishita et al., 2008). In addition to playing a role  
753 in replicative cellular aging, SIRT6 has also been shown to impact  
754 chronological aging in mice, as *SIRT6<sup>-/-</sup>* animals exhibit pheno-  
755 types characteristic of progeroid disorders (Mostoslavsky et al.,  
756 2006). We did not observe any effect on telomere length in an  
757 *npo* mutant strain. These results do not rule out the possibility,  
758 however, that mutation of *npo* might affect other aspects of telo-  
759 mere maintenance or stability. In fact, the aberrations seen at telo-  
760 meres in *SIRT6* knockdown fibroblasts are similar to those seen in  
761 Werner syndrome cells, such as telomere deletions, duplications  
762 and fusions, with no obvious effect on the length of intact telo-  
763 meres (Michishita et al., 2008). Importantly, *N. crassa* has a homo-  
764 log of SIRT6, termed *Neurospora Sirtuin 7 (NST-7)*, not found in  
765 either *S. cerevisiae* or *S. pombe* (Smith et al., 2008). It would be  
766 interesting to know whether NST-7 functions in the same aging  
767 pathway as NPO, and whether maintenance of telomere integrity  
768 is involved.

### 769 3.15. The NPO aging pathway and histone H1

770 The replicative aging phenotype that we observed in the *npo*  
771 mutant is novel for *N. crassa* but similar to that reported for a  
772 strain of the filamentous fungus *Ascoibolus immersus* carrying a si-  
773 lenced epi-allele of the histone H1 (*hh1*) gene, that confers a DNA

774 hypermethylation phenotype (Barra et al., 2000). Although *N.* 774  
775 *crassa hh1* mutants do not display hypermethylation (Folco et 775  
776 al., 2003), it would be interesting to know whether *Neurospora* 776  
777 *hh1* mutants show a decreased replicative lifespan, and if so, 777  
778 whether this involves NPO. Conversely, one could ask whether 778  
779 PARP inhibitors or mutation/silencing of a PARP ortholog would 779  
780 affect replicative aging in *A. immersus*, and if so, whether the 780  
781 pathway is independent of the established hH1 pathway and/or 781  
782 DNA methylation. Kim et al. (2004) showed that PARP-1 associ- 782  
783 ates with chromatin in a manner very similar to hH1: PARP-1 in- 783  
784 creases the nucleosome repeat length and competes with hH1 in 784  
785 nucleosome assembly reactions. Like hH1, binding of PARP-1 to 785  
786 chromatin *in vitro* triggers condensation and transcriptional 786  
787 repression. Unlike hH1, however, PARP-1 dissociates from chro- 787  
788 matin in the presence of NAD<sup>+</sup>, and it has been suggested that 788  
789 localized NAD<sup>+</sup> levels in nuclei might control chromatin structure 789  
790 and transcription (Kim et al., 2004). Results of ChIP-chip experi- 790  
791 ments have shown that actively transcribed promoters have high 791  
792 levels of PARP-1 and low levels of hH1, and that hH1 occupancy is 792  
793 excluded by PARP-1 binding (Krishnakumar et al., 2008). An 793  
794 attractive hypothesis is that PARPs and hH1 provide related func- 794  
795 tions associated with nuclear NAD<sup>+</sup> levels, genome stability and 795  
796 aging. Consistent with this possibility, dramatic loss of hH1 796  
797 accompanies cellular senescence of human fibroblasts (Funayama 797  
798 et al., 2006). While it is intriguing that both PARP and hH1 ortho- 798  
799 logs have been implicated in replicative aging in filamentous fun- 799  
800 gi, there is currently no evidence that fungal PARPs of the PrpA 800  
801 class have the linker histone-like properties of PARP-1. Further- 801  
802 more, they lack an amino terminal DNA-binding domain, which 802  
803 is required for PARP-1 chromatin association. It remains possible, 803  
804 however, that fungal PARPs interact with DNA binding proteins 804  
805 that target them to chromatin. 805

### 806 3.16. NPO might regulate aging in a pathway with Sirtuins

807 The possible function of NSTs in regulation of lifespan in *N. cras-* 807  
808 *sa* has not been investigated. If PARPs impact aging exclusively 808  
809 through indirect effects on the activity of Sirtuins, then our obser- 809  
810 vation that NPO is necessary for normal replicative lifespan in *N.* 810  
811 *crassa* is difficult to reconcile with current models on how Sirtuins 811  
812 regulate aging in yeast and higher organisms. Current models from 812  
813 yeast that assume Sirtuins function exclusively to promote longev- 813  
814 ity would predict that when NAD<sup>+</sup> is limiting, PARylation would in- 814  
815 hibit long lifespan, because NAD<sup>+</sup>-dependent deacetylation and 815  
816 PARylation both consume NAD<sup>+</sup> and produce NAM. Thus, an 816  
817 important question is whether localized NAD<sup>+</sup> levels in nuclei 817  
818 are in fact limiting. If they are not, then NSTs and NPO could pre- 818  
819 sumably act in the same or parallel pathways, with both function- 819  
820 ing to promote longevity. Anderson et al. (2002) found that 820  
821 increasing the levels of NAD<sup>+</sup> salvage pathway proteins in *S. cere-* 821  
822 *visiae* increased telomere and rDNA silencing in a Sir2-dependent 822  
823 manner. Although sir2 deletion mutants were not found to have 823  
824 elevated levels of total cellular NAD<sup>+</sup>, the authors argue that most 824  
825 or all of NAD<sup>+</sup> salvage in *S. cerevisiae* occurs in nuclei, and that nu- 825  
826 clear NAD<sup>+</sup> salvage pathway flux is important in regulation of Sir2 826  
827 deacetylase activity (Anderson et al., 2002). 827

828 Unlike Sir2, PARP-1 can dramatically reduce total cellular NAD<sup>+</sup> 828  
829 levels in response to DNA damage (Zong et al., 2004). If NPO is as 829  
830 robust as PARP-1, and if NAD<sup>+</sup> availability within nuclei is limiting 830  
831 in *N. crassa*, then NSTs and NPO may compete for NAD<sup>+</sup>, and thus 831  
832 function antagonistically in the same aging pathway. However, if 832  
833 it is also assumed that Sirtuins act exclusively to promote longev- 833  
834 ity, as some models suggest, then PARylation should have a nega- 834  
835 tive affect on lifespan, and mutation of *npo* should increase 835  
836 longevity, which is contrary to our observations. 836

837 Recently Fabrizio et al. (2005) have shown that while Sir2 has a  
838 positive impact on replicative lifespan in *S. cerevisiae*, it actually  
839 has a negative impact on chronological lifespan, which is a mea-  
840 sure of how long a non-dividing cell or organism survives. In addi-  
841 tion, while it is generally accepted that Sirtuins positively regulate  
842 longevity in metazoans, SIRT1 may actually function in a pro-aging  
843 pathway (Fabrizio et al., 2005), as *sirt1*<sup>-/-</sup> mice manifest many  
844 phenotypes of long-lived IGF-I-deficient dwarf mice (McBurney  
845 et al., 2003). Furthermore, SIRT1 represses the DAF-16 homolog  
846 FOXO3 (Motta et al., 2004), and this is presumably antagonistic  
847 to longevity (Lin et al., 1997). If the activities of NSTs negatively  
848 regulate replicative lifespan in *N. crassa*, then competition between  
849 NSTs and NPO for NAD<sup>+</sup> could occur, with NPO acting to promote  
850 longevity through inhibition of NSTs.

851 Regardless of whether Sirtuins promote or inhibit longevity, the  
852 general observation that NAD<sup>+</sup>-dependent deacetylases impact  
853 aging in both yeast and metazoans suggests conservation of this  
854 role during evolution. It is therefore reasonable to expect that NSTs  
855 may play a role in *N. crassa* as well. Until such a role has been defi-  
856 nitively established, however, it is not possible to draw conclusions  
857 about the involvement of NSTs in the NPO pathway. Analysis of the  
858 aging phenotypes of *nst* mutants, individually and in combination  
859 with each other and the *npo* mutant, would provide an answer to  
860 these mechanistic questions.

#### 861 Acknowledgments

862 We would like to thank Melissa Hemphill for helping to analyze  
863 *npo/nst* genetic interaction and Wendy Hanna-Rose for comments  
864 on the manuscript. Thanks to Melissa Rolls for expert advice in  
865 confocal imaging. This work was supported by grant GM025690  
866 from the National Institutes of Health to EUS and by Rational Evo-  
867 lutionary Design of Advanced Biomolecules, Saitama Prefecture  
868 Collaboration of Regional Entities for the Advancement of Techno-  
869 logical Excellence, Japan Science and Technology Agency to HI.

#### 870 References

871 Ahel, I., Ahel, D., Matsusaka, T., Clark, A.J., Pines, J., et al., 2008. Poly(ADP-ribose)-  
872 binding zinc finger motifs in DNA repair/checkpoint proteins. *Nature* 451, 81–  
873 85.  
874 Ame, J.C., Rolli, V., Schreiber, V., Niedergang, C., Apiou, F., et al., 1999. PARP-2, a  
875 novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase. *J.*  
876 *Biol. Chem.* 274, 17860–17868.  
877 Ame, J.C., Spelshauer, C., de Murcia, G., 2004. The PARP superfamily. *BioEssays* 26,  
878 882–893.  
879 Ame, J.C., Fouquerel, E., Gauthier, L.R., Biard, D., Boussin, F.D., et al., 2009a.  
880 Radiation-induced mitotic catastrophe in PARC-deficient cells. *J. Cell Sci.* 122,  
881 1990–2002.  
882 Ame, J.C., Hakme, A., Quenet, D., Fouquerel, E., Dantzer, F., et al., 2009b. Detection of  
883 the nuclear poly(ADP-ribose)-metabolizing enzymes and activities in response  
884 to DNA damage. *Method Mol. Biol.* 464, 267–283.  
885 Anderson, R.M., Bitterman, K.J., Wood, J.G., Medvedik, O., Cohen, H., et al., 2002.  
886 Manipulation of a nuclear NAD<sup>+</sup> salvage pathway delays aging without altering  
887 steady-state NAD<sup>+</sup> levels. *J. Biol. Chem.* 277, 18881–18890.  
888 Anderson, R.M., Bitterman, K.J., Wood, J.G., Medvedik, O., Sinclair, D.A., 2003.  
889 Nicotinamide and PNCl<sub>3</sub> govern lifespan extension by calorie restriction in  
890 *Saccharomyces cerevisiae*. *Nature* 423, 181–185.  
891 Aramayo, R., Metzberg, R.L., 1996. Meiotic transvection in fungi. *Cell* 86, 103–113.  
892 Barra, J.L., Rhounim, L., Rossignol, J.L., Faugeron, G., 2000. Histone H1 is dispensable  
893 for methylation-associated gene silencing in *Ascotholus immersus* and essential  
894 for long life span. *Mol. Cell Biol.* 20, 61–69.  
895 Belenky, P., Bogan, K.L., Brenner, C., 2007. NAD<sup>+</sup> metabolism in health and disease.  
896 *Trends Biochem. Sci.* 32, 12–19.  
897 Beneke, S., Burkle, A., 2004. Poly(ADP-ribose)ylation, PARP, and aging. *Sci. Aging*  
898 *Knowledge Environ.* 2004, re9.  
899 Beneke, S., Burkle, A., 2007. Poly(ADP-ribose)ylation in mammalian ageing. *Nucleic*  
900 *Acids Res.* 35, 7456–7465.  
901 Bouchard, V.J., Rouleau, M., Poirier, G.G., 2003. PARP-1, a determinant of cell  
902 survival in response to DNA damage. *Exp. Hematol.* 31, 446–454.  
903 Boulu, R.G., Mesenge, C., Charriaud-Marlangue, C., Verrecchia, C., Plotkine, M., 2001.  
904 Neuronal death: potential role of the nuclear enzyme, poly (ADP-ribose)  
905 polymerase. *Bull. Acad. Natl. Med.* 185, 555–563. discussion 564–555.

Burkle, A., 2000. Poly(ADP-ribose)ylation: a posttranslational protein modification  
906 linked with genome protection and mammalian longevity. *BioGerontology* 1,  
907 41–46.  
908 Burkle, A., 2001a. PARP-1: a regulator of genomic stability linked with mammalian  
909 longevity. *ChemBioChem* 2, 725–728.  
910 Burkle, A., 2001b. Physiology and pathophysiology of poly(ADP-ribose)ylation.  
911 *BioEssays* 23, 795–806.  
912 Burkle, A., Diefenbach, J., Brabeck, C., Beneke, S., 2005. Ageing and PARP. *Pharmacol.*  
913 *Res.* 52, 93–99.  
914 Burzio, L.O., Riquelme, P.T., Koide, S.S., 1979. ADP ribosylation of rat liver  
915 nucleosomal core histones. *J. Biol. Chem.* 254, 3029–3037.  
916 Campisi, J., 2005. Senescent cells, tumor suppression, and organismal aging: good  
917 citizens, bad neighbors. *Cell* 120, 513–522.  
918 Carroll, A.M., Sweigard, J.A., Valent, B., 1994. Improved vectors for selecting  
919 resistance to hygromycin. *Fungal Genet. Newsl.* 41, 22.  
920 Chiarugi, A., Moskowitz, M.A., 2002. Cell biology. PARP-1—a perpetrator of apoptotic  
921 cell death? *Science* 297, 200–201.  
922 D'Amours, D., Desnoyers, S., D'Silva, I., Poirier, G.G., 1999. Poly(ADP-ribose)ylation  
923 reactions in the regulation of nuclear functions. *Biochem. J.* 342 (Pt 2), 249–  
924 268.  
925 Dantzer, F., Schreiber, V., Niedergang, C., Trucco, C., Flatter, E., et al., 1999.  
926 Involvement of poly(ADP-ribose) polymerase in base excision repair. *Biochimie*  
927 81, 69–75.  
928 Davis, R.D., DeSerres, F.J., 1970. Genetic and microbiological research techniques for  
929 *Neurospora crassa*. *Methods Enzymol.* 17, 79–143.  
930 de Murcia, J.M., Niedergang, C., Trucco, C., Ricoul, M., Durrillaux, B., et al., 1997.  
931 Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in  
932 mice and in cells. *Proc. Natl. Acad. Sci. USA* 94, 7303–7307.  
933 Doucet-Chabeaud, G., Gidon, C., Brutesco, C., de Murcia, G., Kazmaier, M., 2001.  
934 Ionising radiation induces the expression of PARP-1 and PARP-2 genes in  
935 *Arabidopsis*. *Mol. Genet. Genomics* 265, 954–963.  
936 Fabrizio, P., Gattazzo, C., Battistella, L., Wei, M., Cheng, C., et al., 2005. Sir2 blocks  
937 extreme life-span extension. *Cell* 123, 655–667.  
938 Folco, H.D., Freitag, M., Ramon, A., Temporini, E.D., Alvarez, M.E., et al., 2003.  
939 Histone H1 is required for proper regulation of pyruvate decarboxylase gene  
940 expression in *Neurospora crassa*. *Eukaryot Cell* 2, 341–350.  
941 Freitag, M., Hickey, P.C., Khalfallah, T.K., Read, N.D., Selker, E.U., 2004a. HP1 is  
942 essential for DNA methylation in *Neurospora*. *Mol. Cell* 13, 427–434.  
943 Freitag, M., Hickey, P.C., Raju, N.B., Selker, E.U., Read, N.D., 2004b. GFP as a tool to  
944 analyze the organization, dynamics and function of nuclei and microtubules in  
945 *Neurospora crassa*. *Fungal Genet. Biol.* 41, 897–910.  
946 Funayama, R., Saito, M., Tanobe, H., Ishikawa, F., 2006. Loss of linker histone H1 in  
947 cellular senescence. *J. Cell Biol.* 175, 869–880.  
948 Gallo, C.M., Smith, D.L., Smith Jr., J.S., 2004. Nicotinamide clearance by Pnc1  
949 directly regulates Sir2-mediated silencing and longevity. *Mol. Cell Biol.* 24,  
950 1301–1312.  
951 Grube, K., Burkle, A., 1992. Poly(ADP-ribose) polymerase activity in mononuclear  
952 leukocytes of 13 mammalian species correlates with species-specific life span.  
953 *Proc. Natl. Acad. Sci. USA* 89, 11759–11763.  
954 Herceg, Z., Wang, Z.Q., 2001. Functions of poly(ADP-ribose) polymerase (PARP) in  
955 DNA repair, genomic integrity and cell death. *Mutat. Res.* 477, 97–110.  
956 Honda, S., Selker, E., 2009. Tools for fungal proteomics: multifunctional *Neurospora*  
957 vectors for gene replacement, protein expression and protein purification.  
958 *Genetics*.  
959 Hong, S.J., Dawson, T.M., Dawson, V.L., 2004. Nuclear and mitochondrial  
960 conversations in cell death: PARP-1 and AIF signaling. *Trends Pharmacol. Sci.*  
961 25, 259–264.  
962 Huletsky, A., de Murcia, G., Muller, S., Hengartner, M., Menard, L., et al., 1989. The  
963 effect of poly(ADP-ribose)ylation on native and H1-depleted chromatin. A role of  
964 poly(ADP-ribose)ylation on core nucleosome structure. *J. Biol. Chem.* 264, 8878–  
965 8886.  
966 Ikejima, M., Noguchi, S., Yamashita, R., Ogura, T., Sugimura, T., et al., 1990. The zinc  
967 fingers of human poly(ADP-ribose) polymerase are differentially required for  
968 the recognition of DNA breaks and nicks and the consequent enzyme activation.  
969 Other structures recognize intact DNA. *J. Biol. Chem.* 265, 21907–21913.  
970 Jeggo, P.A., 1998. DNA repair: PARP – another guardian angel? *Curr. Biol.* 8, R49–  
971 R51.  
972 Kaeberlein, M., McVey, M., Guarente, L., 1999. The SIR2/3/4 complex and SIR2 alone  
973 promote longevity in *Saccharomyces cerevisiae* by two different mechanisms.  
974 *Genes Dev.* 13, 2570–2580.  
975 Karras, G.I., Kustatscher, G., Buhecha, H.R., Allen, M.D., Pugieux, C., et al., 2005. The  
976 macro domain is an ADP-ribose binding module. *EMBO J.* 24, 1911–1920.  
977 Kennedy, B.K., Austriaco Jr., N.R., Zhang, J., Guarente, L., 1995. Mutation in the  
978 silencing gene SIR4 can delay aging in *S. cerevisiae*. *Cell* 80, 485–496.  
979 Kim, M.Y., Mauro, S., Gevry, N., Lis, J.T., Kraus, W.L., 2004. NAD<sup>+</sup> dependent  
980 modulation of chromatin structure and transcription by nucleosome binding  
981 properties of PARP-1. *Cell* 119, 803–814.  
982 Kim, M.Y., Zhang, T., Kraus, W.L., 2005. Poly(ADP-ribose)ylation by PARP-1: 'PAR-  
983 laying' NAD<sup>+</sup> into a nuclear signal. *Genes Dev.* 19, 1951–1967.  
984 Kouzminova, E., Selker, E.U., 2001. dim-2 encodes a DNA methyltransferase  
985 responsible for all known cytosine methylation in *Neurospora*. *EMBO J.* 20,  
986 4309–4323.  
987 Kraus, W.L., Lis, J.T., 2003. PARP goes transcription. *Cell* 113, 677–683.  
988 Krishnakumar, R., Gamble, M.J., Frizzell, K.M., Berrocal, J.G., Kininis, M., et al., 2008.  
989 Reciprocal binding of PARP-1 and histone H1 at promoters specifies  
990 transcriptional outcomes. *Science* 319, 819–821.  
991

- 992 Lamming, D.W., Latorre-Esteves, M., Medvedik, O., Wong, S.N., Tsang, F.A., et al.,  
993 2005. HST2 mediates SIR2-independent life-span extension by calorie  
994 restriction. *Science* 309, 1861–1864.
- 995 Li, B., Navarro, S., Kasahara, N., Comai, L., 2004. Identification and biochemical  
996 characterization of a Werner's syndrome protein complex with Ku70/80 and  
997 poly(ADP-ribose) polymerase-1. *J. Biol. Chem.* 279, 13659–13667.
- 998 Lin, K., Dorman, J.B., Rodan, A., Kenyon, C., 1997. daf-16: an HNF-3/forkhead family  
999 member that can function to double the life-span of *Caenorhabditis elegans*.  
1000 *Science* 278, 1319–1322.
- 1001 Lin, S.J., Defossez, P.A., Guarente, L., 2000. Requirement of NAD and SIR2 for life-  
1002 span extension by calorie restriction in *Saccharomyces cerevisiae*. *Science* 289,  
1003 2126–2128.
- 1004 Lin, S.J., Ford, E., Haigis, M., Liszt, G., Guarente, L., 2004. Calorie restriction extends  
1005 yeast life span by lowering the level of NADH. *Genes Dev.* 18, 12–16.
- 1006 Loros, J.J., Denome, S.A., Dunlap, J.C., 1989. Molecular cloning of genes under control  
1007 of the circadian clock in *Neurospora*. *Science* 243, 385–388.
- 1008 Luo, Z., Freitag, M., Sachs, M.S., 1995. Translational regulation in response to  
1009 changes in amino acid availability in *Neurospora crassa*. *Mol. Cell Biol.* 15, 5235–  
1010 5245.
- 1011 Margolin, B.S., Freitag, M., Selker, E.U., 1997. Improved plasmids for targeting at the  
1012 his-3 locus of *Neurospora crassa* by electroporation. *Fungal Genet. Newsl.* 47,  
1013 112.
- 1014 Margolin, B.S., Garrett-Engele, P.W., Stevens, J.N., Fritz, D.Y., Garrett-Engele, C., et al.,  
1015 1998. A methylated *Neurospora* 5S rRNA pseudogene contains a transposable  
1016 element inactivated by repeat-induced point mutation. *Genetics* 149, 1787–  
1017 1797.
- 1018 Masutani, M., Nakagama, H., Sugimura, T., 2003. Poly(ADP-ribose) and  
1019 carcinogenesis. *Genes Chromosomes Cancer* 38, 339–348.
- 1020 McBurney, M.W., Yang, X., Jardine, K., Hixon, M., Boekelheide, K., et al., 2003. The  
1021 mammalian SIR2alpha protein has a role in embryogenesis and gametogenesis.  
1022 *Mol. Cell Biol.* 23, 38–54.
- 1023 McNally, M.T., Free, S.J., 1988. Isolation and characterization of a *Neurospora*  
1024 glucose-repressible gene. *Curr. Genet.* 14, 545–551.
- 1025 Meder, V.S., Boegli, M., de Murcia, G., Schreiber, V., 2005. PARP-1 and PARP-2  
1026 interact with nucleophosmin/B23 and accumulate in transcriptionally active  
1027 nucleoli. *J. Cell Sci.* 118, 211–222.
- 1028 Menissier de Murcia, J., Ricoul, M., Tartier, L., Niedergang, C., Huber, A., et al., 2003.  
1029 Functional interaction between PARP-1 and PARP-2 in chromosome stability  
1030 and embryonic development in mouse. *EMBO J.* 22, 2255–2263.
- 1031 Miao, V.P., Freitag, M., Selker, E.U., 2000. Short TpA-rich segments of the zeta-eta  
1032 region induce DNA methylation in *Neurospora crassa*. *J. Mol. Biol.* 300, 249–  
1033 273.
- 1034 Michishita, E., McCord, R.A., Berber, E., Kioi, M., Padilla-Nash, H., et al., 2008. SIRT6 is  
1035 a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. *Nature*  
1036 452, 492–496.
- 1037 Mortimer, R.K., Johnston, J.R., 1959. Life span of individual yeast cells. *Nature* 183,  
1038 1751–1752.
- 1039 Mostoslavsky, R., Chua, K.F., Lombard, D.B., Pang, W.W., Fischer, M.R., et al., 2006.  
1040 Genomic instability and aging-like phenotype in the absence of mammalian  
1041 SIRT6. *Cell* 124, 315–329.
- 1042 Motta, M.C., Divecha, N., Lemieux, M., Kamel, C., Chen, D., et al., 2004. Mammalian  
1043 SIRT1 represses forkhead transcription factors. *Cell* 116, 551–563.
- 1044 Ninomiya, Y., Suzuki, K., Ishii, C., Inoue, H., 2004. Highly efficient gene replacements  
1045 in *Neurospora* strains deficient for nonhomologous end-joining. *Proc. Natl.*  
1046 *Acad. Sci. USA* 101, 12248–12253.
- 1047 Ogata, N., Ueda, K., Kawaichi, M., Hayaishi, O., 1981. Poly(ADP-ribose) synthetase, a  
1048 main acceptor of poly(ADP-ribose) in isolated nuclei. *J. Biol. Chem.* 4135–4137.
- 1049 Osiewacz, H.D., 2002. Aging in fungi: role of mitochondria in *Podospora anserina*.  
1050 *Mech. Ageing Dev.* 123, 755–764.
- 1051 Panzeter, P.L., Althaus, F.R., 1990. High resolution size analysis of ADP-ribose  
1052 polymers using modified DNA sequencing gels. *Nucleic Acids Res.* 18, 2194.
- 1053 Pieper, A.A., Verma, A., Zhang, J., Snyder, S.H., 1999. Poly(ADP-ribose) polymerase,  
1054 nitric oxide and cell death. *Trends Pharmacol. Sci.* 20, 171–181.
- 1055 Povirk, L.F., Wubter, W., Kohnlein, W., Hutchinson, F., 1977. DNA double-strand  
1056 breaks and alkali-labile bonds produced by bleomycin. *Nucleic Acids Res.* 4,  
1057 3573–3580.
- 1058 Reale, A., Matteis, G.D., Galleazzi, G., Zampieri, M., Caiafa, P., 2005. Modulation of  
1059 DNMT1 activity by ADP-ribose polymers. *Oncogene* 24, 13–19.
- 1060 Riquelme, P.T., Burzio, L.O., Koide, S.S., 1979. ADP ribosylation of rat liver lysine-rich  
1061 histone in vitro. *J. Biol. Chem.* 254, 3018–3028.
- Rogina, B., Helfand, S.L., 2004. Sir2 mediates longevity in the fly through a pathway  
related to calorie restriction. *Proc. Natl. Acad. Sci. USA* 101, 15998–16003.
- Rountree, M.R., Selker, E.U., 1997. DNA methylation inhibits elongation but not  
initiation of transcription in *Neurospora crassa*. *Genes Dev.* 11, 2383–2395.
- Sandmeier, J.J., Celic, I., Boeke, J.D., Smith, J.S., 2002. Telomeric and rDNA silencing in  
*Saccharomyces cerevisiae* are dependent on a nuclear NAD(+) salvage pathway.  
*Genetics* 160, 877–889.
- Selker, E.U., 1990. Premeiotic instability of repeated sequences in *Neurospora crassa*.  
*Annu. Rev. Genet.* 24, 579–613.
- Selker, E.U., 2004. Genome defense and DNA methylation in *Neurospora*. *Cold*  
*Spring Harb. Symp. Quant. Biol.* 69, 119–124.
- Selker, E.U., Fritz, D.Y., Singer, M.J., 1993. Dense nonsymmetrical DNA methylation  
resulting from repeat-induced point mutation in *Neurospora*. *Science* 262,  
1724–1728.
- Selker, E.U., Tountas, N.A., Cross, S.H., Margolin, B.S., Murphy, J.C., et al., 2003. The  
methylated component of the *Neurospora crassa* genome. *Nature* 422, 893–897.
- Semighini, C.P., Savoldi, M., Goldman, G.H., Harris, S.D., 2006. Functional  
characterization of the putative *Aspergillus nidulans* poly(ADP-ribose)  
polymerase homolog PrpA. *Genetics* 173, 87–98.
- Shieh, W.M., Ame, J.C., Wilson, M.V., Wang, Z.Q., Koh, D.W., et al., 1998. Poly(ADP-  
ribose) polymerase null mouse cells synthesize ADP-ribose polymers. *J. Biol.*  
*Chem.* 273, 30069–30072.
- Shimokawa, T., Masutani, M., Nagasawa, S., Nozaki, T., Ikota, N., et al., 1999.  
Isolation and cloning of rat poly(ADP-ribose) glycohydrolase: presence of a  
potential nuclear export signal conserved in mammalian orthologs. *J. Biochem.*  
126, 748–755.
- Shiu, P.K., Raju, N.B., Zickler, D., Metzberg, R.L., 2001. Meiotic silencing by  
unpaired DNA. *Cell* 107, 905–916.
- Sinclair, D.A., Guarente, L., 1997. Extrachromosomal rDNA circles—a cause of aging  
in yeast. *Cell* 91, 1033–1042.
- Smith, K.M., Kothe, G.O., Matsen, C.B., Khlafallah, T.K., Adhvaray, K.K., et al., 2008.  
The fungus *Neurospora crassa* displays telomeric silencing mediated by multiple  
sirtuins and by methylation of histone H3 lysine 9. *Epigenet. Chromatin* 1.
- Smulson, M.E., Simbulan-Rosenthal, C.M., Boulares, A.H., Yakovlev, A., Stoica, B.,  
et al., 2000. Roles of poly(ADP-ribose)ylation and PARP in apoptosis, DNA repair,  
genomic stability and functions of p53 and E2F-1. *Adv. Enzyme Regul.* 40, 183–  
215.
- Tamaru, H., Selker, E.U., 2001. A histone H3 methyltransferase controls DNA  
methylation in *Neurospora crassa*. *Nature* 414, 277–283.
- Tissenbaum, H.A., Guarente, L., 2001. Increased dosage of a sir-2 gene extends  
lifespan in *Caenorhabditis elegans*. *Nature* 410, 227–230.
- Trucco, C., Oliver, F.J., de Murcia, G., Menissier-de Murcia, J., 1998. DNA repair defect  
in poly(ADP-ribose) polymerase-deficient cell lines. *Nucleic Acids Res.* 26,  
2644–2649.
- Tsuchiya, M., Dang, N., Kerr, E.O., Hu, D., Steffen, K.K., et al., 2006. Sirtuin-  
independent effects of nicotinamide on lifespan extension from calorie  
restriction in yeast. *Aging Cell* 5, 505–514.
- Tulin, A., Stewart, D., Spradling, A.C., 2002. The *Drosophila* heterochromatic gene  
encoding poly(ADP-ribose) polymerase (PARP) is required to modulate  
chromatin structure during development. *Genes Dev.* 16, 2108–2119.
- Verdun, R.E., Karlseder, J., 2007. Replication and protection of telomeres. *Nature*  
447, 924–931.
- von Kobbe, C., Harrigan, J.A., Schreiber, V., Stiegler, P., Piotrowski, J., et al., 2004.  
Poly(ADP-ribose) polymerase 1 regulates both the exonuclease and helicase  
activities of the Werner syndrome protein. *Nucleic Acids Res.* 32, 4003–4014.
- Wang, Z.Q., Auer, B., Stingl, L., Berghammer, H., Haidacher, D., et al., 1995. Mice  
lacking ADPRT and poly(ADP-ribose)ylation develop normally but are  
susceptible to skin disease. *Genes Dev.* 9, 509–520.
- Wang, Z.Q., Stingl, L., Morrison, C., Jantsch, M., Los, M., et al., 1997. PARP is  
important for genomic stability but dispensable in apoptosis. *Genes Dev.* 11,  
2347–2358.
- Watanabe, K., Sakuraba, Y., Inoue, H., 1997. Genetic and molecular characterization  
of *Neurospora crassa* mus-23: a gene involved in recombinational repair. *Mol.*  
*Gen. Genet.* 256, 436–445.
- Watanabe, F., Fukazawa, H., Masutani, M., Suzuki, H., Teraoka, H., et al., 2004.  
Poly(ADP-ribose) polymerase-1 inhibits ATM kinase activity in DNA damage  
response. *Biochem. Biophys. Res. Commun.* 319, 596–602.
- Zong, W.X., Ditsworth, D., Bauer, D.E., Wang, Z.Q., Thompson, C.B., 2004. Alkylating  
DNA damage stimulates a regulated form of necrotic cell death. *Genes Dev.* 18,  
1272–1282.





ELSEVIER

doi:10.1016/j.ijrobp.2009.11.005

**BIOLOGY CONTRIBUTION**

**CLONALLY EXPANDING THYMOCYTES HAVING LINEAGE CAPABILITY IN GAMMA-RAY-INDUCED MOUSE ATROPHIC THYMUS**

TAKASHI YAMAMOTO, M.D.,\*† SHIN-ICHI MORITA, M.D.,\*† ERIKA GO, D.D.S.,\* MIKI OBATA, B.SCI.,\*  
YOSHINORI KATSURAGI, PH.D.,\* YUKARI FUJITA, M.SCI.,\* YOSHITAKA MAEDA, B.SCI.,‡  
MINESUKE YOKOYAMA, PH.D.,‡ YUTAKA AOYAGI, M.D., PH.D.,† HITOSHI ICHIKAWA, PH.D.,§  
YUKIO MISHIMA, PH.D.,\* AND RYO KOMINAMI, M.D., PH.D.\*

\*Department of Molecular Genetics and †3rd Internal Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan; ‡Center for Bioresource-Based Researches, Brain Research Institute, Niigata, Japan; and §Genetics Division, National Cancer Center Research Institute, Tokyo, Japan

**Purpose:** To characterize, in the setting of  $\gamma$ -ray-induced atrophic thymus, probable prelymphoma cells showing clonal growth and changes in signaling, including DNA damage checkpoint.

**Methods and Materials:** A total of 111 and 45 mouse atrophic thymuses at 40 and 80 days, respectively, after  $\gamma$ -irradiation were analyzed with polymerase chain reaction for D-J rearrangements at the *TCR $\beta$*  locus, flow cytometry for cell cycle, and Western blotting for the activation of DNA damage checkpoints.

**Results:** Limited D-J rearrangement patterns distinct from normal thymus were detected at high frequencies (43 of 111 for 40-day thymus and 21 of 45 for 80-day thymus). Those clonally expanded thymocytes mostly consisted of CD4<sup>+</sup>CD8<sup>+</sup> double-positive cells, indicating the retention of lineage capability. They exhibited pausing at a late G1 phase of cell cycle progression but did not show the activation of DNA damage checkpoints such as  $\gamma$ H2AX, Chk1/2, or p53. Of interest is that 17 of the 52 thymuses showing normal D-J rearrangement patterns at 40 days after irradiation showed allelic loss at the *Bcl11b* tumor suppressor locus, also indicating clonal expansion.

**Conclusion:** The thymocytes of clonal growth detected resemble human chronic myeloid leukemia in possessing self-renewal and lineage capability, and therefore they can be a candidate of the lymphoma-initiating cells. © 2010 Elsevier Inc.

Gamma-ray-induced mouse thymic lymphoma, Prelymphoma, DNA damage response, Bcl11b, Cancer stem cells.

**INTRODUCTION**

Premalignant conditions are recognizable lesions that are strongly associated with the development of malignant neoplasia. One such lesion must exist in  $\gamma$ -ray-induced mouse atrophic thymus because mice that received thymocytes from the atrophic thymus developed thymic lymphomas at a high frequency (1, 2). Immature thymocytes in the thymus proliferate and undergo  $\beta$ -selection at CD4<sup>+</sup> and CD8<sup>-</sup> double-negative stage and differentiate into double-positive (DP) cells, which further differentiate into CD4<sup>+</sup> or CD8<sup>+</sup> single-positive cells (3, 4). The thymus controls the cellular fate of thymocytes, including the elimination of unfavorable cells that are generated during developmental and pathologic processes (5).

Chronic myeloid leukemia (CML) may have a characteristic of the premalignant condition because CML cells differen-

tiate to mature, nontumorigenic blood cells though possessing intrinsic self-renewal capability (6, 7). The transition from the CML chronic phase to the aggressive blast crisis phase requires the arrest of differentiation. Because CML arises from hematopoietic stem cell-like progenitors, it is thought to conform well to the cancer stem cell model (8). As described above, because of the tumorigenic capability of thymocytes in the atrophic thymus, thymocytes might contain cancer stem cells or lymphoma-initiating cells. The importance of leukemia-initiating cells is pointed out in relapsed acute lymphoblastic leukemia in humans, in that the cells responsible for relapse are ancestral to the primary leukemia cells (9).

Normal cells can perceive and arrest aberrant cycles of cell division that are triggered by cancer-promoting stimuli. A hallmark of precancerous cells in major human cancer types is aberrant stimulation of cell proliferation that results in

Reprint requests: Ryo Kominami, M.D., Department of Molecular Genetics, Niigata University Graduate School of Medical and Dental Sciences, Asahimachi 1-757, Chuo-ku, Niigata 951-8510, Japan. Tel: (+81) 25-227-2077; Fax: (+81) 25-227-0757; E-mail: rykominami@med.niigata-u.ac.jp

T.Y. and S.M. contributed equally to this work.

This work was supported by grants-in-aid for Cancer Research from the Ministries of Education, Science, Art and Sports, and Health and Welfare of Japan.

Conflict of interest: none.

Received Aug 20, 2009, and in revised form Nov 5, 2009. Accepted for publication Nov 7, 2009.